 
 
A PHASE IB TRIAL OF PEMBROLIZUMAB (MK -3475) AND TRAMETINIB 
FOCUSED ON ADVANCED KRAS MUTANT NON- SMALL CELL LUNG CANCER  
 
Funding Sources:  [COMPANY_006] &  Co., Inc. [study ID  TBD ] 
 [COMPANY_001] [study ID TBD ] 
 
Protocol Number(s):  UCDCC#259; ([COMPANY_006]); ([COMPANY_001]) 
 Phase:  1 
 
Principal Investigator:  [INVESTIGATOR_216668],  MD, MS 
UC Davis Comprehensive Cancer  Center  
[ADDRESS_260447]  
Sacramento,  CA [ZIP_CODE] 
Telephone: ([PHONE_4584] Fax: ([PHONE_4585]  
[EMAIL_4233]
 
 
Co-Investigators: David Gandara, MD   
UC Davis Comprehensive Cancer  Center  
[ADDRESS_260448]  
Sacramento,  CA [ZIP_CODE] 
Telephone: ([PHONE_4584] Fax: ([PHONE_4585]  
[EMAIL_4234]
 
 Karen Kelly, MD  
UC Davis  Comprehensive Cancer Center  
[ADDRESS_260449], Sacramento, CA [ZIP_CODE] 
Telephone: ([PHONE_4584] 
Fax: ([PHONE_4585] karkelly@ucda vis.edu
 
 Primo N. Lara, Jr. MD  
UC Davis  Comprehensive Cancer Center  
[ADDRESS_260450], Sacramento, CA [ZIP_CODE] Telephone: ([PHONE_4584] 
Fax: ([PHONE_4585] 
[EMAIL_4235]
 
 Statistician:   Laurel Beckett, PhD  
Division of Biostatistics, MS1C  
University of [LOCATION_004] Davis  
One Shields Avenue 
Davis, CA [ZIP_CODE]  
[EMAIL_4236]
 
  
Products:  Pembrolizumab/Trametinib   UCDCC#259  
  v.Original (05/09/2017)  
 
UC Davis Comprehensi ve Cancer Center  
Confidential   Page 2 of 87 IND NUMBER: TBD  
 
IND Sponsor:  UC Davis Comprehensive Cancer Center  
 Version No./Date:  Original  / May 9 , 2017  
 
Participating Site (s):  Select SU2C Sites  
 
    
Products:  Pembrolizumab/Trametinib   UCDCC#259  
  v.Original (05/09/2017)  
 
UC Davis Comprehensi ve Cancer Center  
Confidential   Page 3 of 87 INVESTIGATOR SIGNATURE [CONTACT_118258]:  UCDCC#259 Protocol Title : A Phase Ib Trial of Pembrolizumab (MK-3475) and  Trametinib Focused on 
Advanced K RAS  Mutant Non- Small Cell Lung Cancer  
I have read this protocol and agree that it contains all necessary details for carrying out this 
study. I will conduct the study as outlined herein and will complete the study within the time designated, in accordance with all stipulations of the protocol and in accordance with Good Clinical Practices, local regulatory requirements, and the Declaration of Helsinki.  
I will provide copi[INVESTIGATOR_216669] y. I will discuss this material with them to ensure that 
they are fully informed regarding the study agent(s) and the conduct of the study.  
 __________________________________ 
Investigator Name (print)  
__________________________________ Investigator Signature  
_____________________ Date  
 
  
Products:  Pembrolizumab/Trametinib   UCDCC#259  
  v.Original (05/09/2017)  
 
UC Davis Comprehensi ve Cancer Center  
Confidential   Page [ADDRESS_260451] of Abbreviations  .................................................................................................................................... 6 
1.0 TRIAL SUMMARY  ........................................................................................................................ 8 
2.0 TRIAL DESIGN  .............................................................................................................................. 9 
2.1 Trial Design  ................................................................................................................................. 9 
2.2 Trial Diagram  .............................................................................................................................. 9 
3.0 OBJECTIVES & HYPOTHESES ................................................................................................. 10 
3.1 Primary Objective & Hypotheses  .............................................................................................. 10 
3.2 Secondary Objective & Hypotheses .......................................................................................... 10 
3.3 Exploratory Objective ............................................................................................................... 10 
4.0 BACKGROUND & RATIONALE  ............................................................................................... 10 
4.1 Pembrolizumab (MK-3475) ...................................................................................................... 10 
4.2 Trametinib  ................................................................................................................................. 12 
4.3 Rationale  .................................................................................................................................... 12 
5.0 METHODOLOGY ........................................................................................................................ 18 
5.1 Entry Criteria  ............................................................................................................................. 18 
5.2 Trial Treatments  ........................................................................................................................ 22 
5.3 Treatment  ................................................................................................................................... 33 
5.4 Definition of Dose Limiting Toxicities  ..................................................................................... 33 
5.5 Concomitant Medications/Vaccinations (allowed & prohibited) .............................................. 35 
5.6 Rescue Medications & Supportive Care  .................................................................................... 36 
5.7 Diet/Activity/Other Considerations  ........................................................................................... [ADDRESS_260452] Withdrawal/Discontinuation Criteria  ........................................................................... [ADDRESS_260453] Replacement Strategy  ................................................................................................... 45 
5.10  Clinical Criteria for Early Trial Termination  ............................................................................ 45 
6.0 Study Calendar ............................................................................................................................... 46 
7.0 TRIAL PROCEDURES  ................................................................................................................. 48 
7.1 Trial Procedures......................................................................................................................... 48 
7.2 Assessing and Recording Adverse Events ................................................................................. 62 
8.0 STATISTICAL ANALYSIS PLAN  .............................................................................................. 70 
9.0 LABELING, PACKAGING, STORAGE AND RETURN OF CLINICAL SUPPLIES  .............. 73 
9.1 Pembrolizumab .......................................................................................................................... 73 
9.2 Trametinib  ................................................................................................................................. 73 
9.3 Packaging and Labeling Information ........................................................................................ 74 
9.4 Clinical Supplies Disclosure  ...................................................................................................... 74 
9.5 Storage and Handling Requirements ......................................................................................... 74 
9.6 Returns and Reconciliation  ........................................................................................................ 75 
10.0  ADMINISTRATIVE AND REGULATORY DETAILS  .............................................................. 75 
10.1  Confidentiality  ........................................................................................................................... 75 
10.2  Good Clinical Practice  ............................................................................................................... 75 
10.3  Patient Information and Informed Consent ............................................................................... 75 
10.4  Records and Retention ............................................................................................................... 76 
Products:  Pembrolizumab/Trametinib   UCDCC#259  
  v.Original (05/09/2017)  
 
UC Davis Comprehensi ve Cancer Center  
Confidential   Page 5 of 87 10.5  Data and Safety Monitoring ...................................................................................................... 76 
10.6  Compliance with Law and Regulations ..................................................................................... 77 
10.7  Compliance with Trial Registration and Results Posting Requirements  ................................... 77 
10.8  Quality Management System  .................................................................................................... 77 
11.0  Appendices ..................................................................................................................................... 78 
11.1  Multisite Patient Registration  .................................................................................................... 78 
11.2  Data Management  ...................................................................................................................... 79 
11.3  ECOG Performance Status  ........................................................................................................ 80 
11.4  FRIDERICIA’S CRITERIA FOR QTC CALCULATION ....................................................... 81 
11.5  [LOCATION_001] Heart Association Classification of Heart Failure  ................................................... 82 
11.6  Common Terminology Criteria for Adverse Events V4.0 (CTCAE)  ........................................ 83 
11.7  Response Evaluation Criteria in Solid Tumors (RECIST) 1.[ADDRESS_260454] permitted Trametinib dose will be 1.5 mg daily. .. 24 Table 5. Dose Modification Guidelines for Pembrolizumab (MK-3475) for Drug- Related Adverse 
Events  ...................................................................................................................................... 24 
Table 6 Dose Modification Guidelines for Trametinib for Drug -Related Adverse Events (Unless 
Otherwise Specified)  ............................................................................................................... 26 
Table 7. Tra metinib Dose Modification Guidelines and Stoppi[INVESTIGATOR_216670]  ............. 27 
Table 8. Trametinib Withholding and Stoppi[INVESTIGATOR_216671] ...................................... 28 
Table 9. Trametinib Dose Modification Guidelines for Hypertension  .................................................... 28 
Table 10. Management and Trametinib Dose Modification for Visual Changes and/or Ophthalmic 
Examination Findings .............................................................................................................. 29 
Table 11. Trametinib Dose Modification for RPED  ................................................................................ 29 
Table 12. Management and Dose Modification Guidelines for Diarrhea  ................................................ 30 
Table 13. Dose Modification Guidelines and Management for Rash ...................................................... 31  
Tab
le 14. Pneumonitis Guidelines ........................................................................................................... 32 
Table 15: Dose Escalation Decision Rule Summary  ............................................................................... [ADDRESS_260455] OF FIGURES  
Figure 1 . Response rates to pembrolizumab according to mutation status ............................................ 14 
Figure 2 . In vivo antitumor activity in CT26 Mouse Model dependent on sequencing of MEK 
inhibition with trametinib and PD- 1 blockade (Liu et al, Clinical Cancer Research 2015)  ...... 14 
Products:  Pembrolizumab/Trametinib   UCDCC#259  
  v.Original (05/09/2017)  
 
UC Davis Comprehensi ve Cancer Center  
Confidential   Page [ADDRESS_260456]  aspartate aminotransferase  
ALT  alanine aminotransferase  
BAL  bronchoalveolar lavage  
β-HCG3  β-human chorionic gonadotropin  
BID  twice daily  
CBC  complete blood count  
CLIA  Clinical Laboratory Improvement Amendments  
CNS  central nervous system  
CR complete response  
CRF  case report form (paper or electronic as appropriate for this study)  
CSR  central serous retinopathy  
CT computed tomography  
DKA diabetic ketoacidosis  
DLT  dose limiting toxicity  
DMSO  dimethyl sulfoxide  
DNA deoxyribonucleic acid  
DSMB  UCDCC Data and Safety Monitoring Board  
ECI events of clinical interest  
ECOG  Eastern Cooperative Oncology Group  
EGFR  Epi[INVESTIGATOR_216672] -regula ted kinase  
EU European Union  
FDA  Food and Drug Administration 
FDAAA Food and Drug Administration Amendments Act  
FDAMA  Food and Drug Administration Modernization Act  
FFPE  formalin -fixed, paraffin -embedded  
GCP  Good Clinical Practice  
HBsAg  hepatitis B sur face antigen  
HCV  Hepatitis C  
H&E  hematoxylin & eosin  
HIV Human Immunodeficiency Virus  
IB investigator's brochure  
ICH International Conference on Harmonisation  
IHC immunohistochemistry  
INR international normalized ratio  
IRB institutional review board  
ITIM immunoreceptor tyrosine -based inhibition motif  
ITSM  immunoreceptor tyrosine -based switch motif  
IV intraveinous  
LDH  lactate dehydrogenase  
LLN  lower limit of normal  
mAb  monoclonal antibody  
MEK  mitogen -activated extracellular signal -regulated kinase  
MK- 3475 pembrolizumab  
MTD  maximum tolerated dose  
NCI CTCAE  National Cancer Institute Common Terminology for Adverse Events  
NSAIDS  nonsteroidal anti -inflammatory drugs  
NSCLC  non-small cell lung cancer  
Products:  Pembrolizumab/Trametinib   UCDCC#259  
  v.Original (05/09/2017)  
 
UC Davis Comprehensi ve Cancer Center  
Confidential   Page [ADDRESS_260457]  Response Evaluation Criteria In Solid Tumors  
RP2D  recommended phase II dose  
RPED  retinal pi[INVESTIGATOR_216673]2C  Stand Up to Cancer  
T3 total thriiodothyronine  
T4 free thyroxine  
T1DM  Type 1 diabetes melli tus  
TB Bacillus tuberculosis  
TIL tumor -infiltrating lymphocytes  
TKI tyrosine kinase inhibitors  
TSH  thyroid stimulating hormone  
UCD  University of [LOCATION_004], Davis; UC Davis  
UCDCC  UC Davis Comprehensive Cancer Center  
ULN  upper limit of normal  
 
  
Products:  Pembrolizumab/Trametinib   UCDCC#259  
  v.Original (05/09/2017)  
 
UC Davis Comprehensi ve Cancer Center  
Confidential   Page 8 of 87 1.0 TRIAL SUMMARY  
Abbreviated Title  A Phase Ib Trial of Pembrolizumab and Trametinib Focused on 
Advanced KRAS mutant Non-Small Cell Lung Cancer  
Trial Phase  Ib 
Clinical Indication  Advanced Non -Small Cell Lung Cancer Harboring a KRAS mutation  
Trial Type  Phase Ib w ith Expansion Cohorts  
Route of administration  Pembrolizumab ( MK-3475 ) (Intravenous)  
Trametinib (Oral)  
Trial Blinding  Unblinded Open -label  
Treatment Groups  Phase  I dose escalation of combination Pembrolizumab and Trametinib 
with lead in trametinib (cohort A) or lead in pembrolizumab (cohort B) 
in advanced NSCLC patients to determine the MTD and expansion 
phase dose.  
At the MTD, there are two Expansion Cohorts in KRAS Mutant NSCLC 
as follows:  
Cohort A: Lead in intermittent Trametinib for 1 cycle (3 weeks) followed by [CONTACT_216704] B: Lead in Pembrolizumab for 1 cycle (3 weeks) followed by [CONTACT_216705] 42 evaluable patients total (9 in each dose escalation cohort 
and 24 patients total for the dose expansion cohorts. A minimum of 12 
patients (i.e., only 6 in each dose escalation arm if trial is terminated 
early due to  unacceptable toxicity) and a maximum of 62 patients (1 8 
patients in each dose escalation cohort and 24 patients total for the  dose 
expansion cohort s.)  
Estimated enrollment period  2 years  
Estimated duration of trial  3 years  
Duration of Participation  3 years  
 
 
  
Products:  Pembrolizumab/Trametinib   UCDCC#259  
  v.Original (05/09/2017)  
 
UC Davis Comprehensi ve Cancer Center  
Confidential   Page [ADDRESS_260458] progressed on prior platinum- based frontline therapy. After the 
initial dose escalation  with two different sequencing schemes (lead in trametinib and lead in 
pembrolizumab), in the expansion cohorts patients will be allocated to one of these two different 
arms: a) lead in trametinib followed by [CONTACT_216706]/pembrolizumab and b) lead in 
pembrolizumab followed by [CONTACT_216707] , to determine the RP2D, to assess initial estimates of efficacy and to 
examine in the tumor and immune microenvironment changes in PD -L1 expression and T- cell 
subsets) across the se two different sequencing schemes. Safety findings and preliminary efficacy  
will be employed  as primary criteria for whether one or  both treatment sequences may warrant 
further study. Exploratory immune correlates will be ex amined  as secondary criteria to inform 
further development of this approach in future studies. The treatment arm that provides the better 
RR, PFS, safety profile and enhanced tumor immune microenvironment at rebiopsy will be recommended for further development. It is anticipated that ORR ≥ 50% or a median PFS ≥ [ADDRESS_260459] 1.1 guidelines or intolerable toxicity.  
2.2 Trial Diagram 
  
Intercalated Trametinib and Pembrolizumab in Advanced KRAS Mutant NSCLC  
Advanced NSCLC PD 
after Pt-based chemo  
(KRAS mutant for 
expansion).  
 
3+3 dose escalation to 
MTD in Arm A and 
Arm B.  
 
Starting dose level:  
trametinib 1.5 mg 
daily.  
Arm B:  
Lead in  Pembrolizumab  
(N=12)  
•Add trametinib  
(Cycle 2)Intercalated 
trametinib and 
pembrolizumab after 
C1* 
•Disease assessment 
every 9 weeks.  
•Add pembrolizumab  
(Cycle 2)  
•Intercalated trametinib 
and pembrolizumab after C1*  
•Disease assessment  
every 9 weeks  
* Dose escalation in Arm A and Arm B followed by [CONTACT_216708] (see 8.0 Statistical Analysis Plan).  
  Trametinib starting 10 days on and 11 days off.  Starting dose level 1.5 mg daily.  
  Paired biopsy baseline, D11, and at progression (optional).  
  Pt=platinum, PD=progressive disease, MTD=maximum tolerated dose, NSCLC=non -small cell lung cancer  
Arm A:  
Lead in Trametinib  
(N=12)  
Products:  Pembrolizumab/Trametinib   UCDCC#259  
  v.Original (05/09/2017)  
 
UC Davis Comprehensi ve Cancer Center  
Confidential   Page 10 of 87 3.0 OBJECTIVES & HYPOTHESES 
3.1 Primary Objective & Hypotheses  
Objective:  To evaluate the safety and tolerability  of pembrolizumab ( MK-3475) when given in 
combination with trametinib in the proposed sequencing schemes in patients with advanced or 
metastatic non -small cell lung cancer with KRAS mutations.  
Hypothesis:   We hypothesize that pembrolizumab in combination with trametinib  given with our 
lead in and intermittent sequencing schemes  will be safe and tolerable.  
3.2 Secondary Objective & Hypotheses  
Objective:  To assess in a preliminary manner the clinical efficacy of the se combinations with 
the proposed sequencing schemes outlined above including overall response rate and progression 
free survival.  
Hypothesis for Secondary Objective:  We hypothesize that the combination of trametinib and 
pembrolizumab will be efficacious.  
3.3 Exploratory Objective 
Objective:  To determine in an exploratory manner changes in PD- L1 expression as well as  other 
immune correlates induced by [CONTACT_216709]. 
Hypothesis for Exploratory Objective :  We hypothesize that lead in trametinib will 
demonstrate the most promise for preliminary efficacy based on clinical outcome and changes in 
immune  micro -environment. 
 
4.0 BACKGROUND & RATIONALE  
4.1 Pembrolizumab (MK -3475) 
4.1.1 Background 
Refer to the Investigator’s Brochure (IB)/approved labeling for detailed background information 
on pembrolizumab. 
4.1.[ADDRESS_260460] immune surveillance in controlling outgrowth of neoplastic 
transformatio n has been known for decades.  Accumulating evidence shows a correlation 
between tumor-infiltrating lymphocytes (TILs) in cancer tissue and favorable prognosis in various malignancies.  In particular, the presence of CD8+ T -cells and the ratio of CD8+ effector 
T-cells / FoxP3+ regulatory T -cells seems to correlate with improved prognosis and long- term 
survival in many solid tumors. 
Products:  Pembrolizumab/Trametinib   UCDCC#259  
  v.Original (05/09/2017)  
 
UC Davis Comprehensi ve Cancer Center  
Confidential   Page [ADDRESS_260461] hijacked by [CONTACT_13207].  The normal function of PD- 1, expressed on the cell surface of activated T -cells under 
healthy conditions, is to down-modulate unwanted or excessive immune responses, including 
autoimmune reactions.  PD-1 (encoded by [CONTACT_13228]1) is an Ig superfamily member related to CD28 and CTLA-4 which has been shown to negatively regulate antigen receptor signaling upon enga gement of its ligands (PD -L1 and/or PD -L2).  The structure of murine PD-1 has been 
resolved .  PD-1 and family members are type I transmembrane glycoproteins containing an Ig 
Variable -type (V -type) domain responsible for ligand binding and a cytoplasmic tai l which is 
responsible for the binding of signaling molecules.  The cytoplasmic tail of PD-1 contains 2 tyrosine-based signaling motifs, an immunoreceptor tyrosine-based inhibition motif (ITIM) and an immunoreceptor tyrosine-based switch motif (ITSM).  Following T- cell stimulation, PD -[ADDRESS_260462] from that of CTLA -4 as both molecules 
regulate an overlappi[INVESTIGATOR_77971].  PD-1 was shown to be expressed on activated lymphocytes includi ng peripheral CD4+ and CD8+ T -cells, B -cells, T regs a nd Natural Killer 
cells.  Expression has also been shown during thymic development on CD4- CD8 - (double 
negative) T -cells as well as subsets of macr ophages and dendritic cells.  The ligands for PD-1 
(PD-L1 and PD- L2) are constitutively expressed or can be induced in a variety of cell types, 
including non- hematopoietic tissues as well as in  various tumors.  Both ligands are type I 
transmembrane receptors containing both IgV- and IgC -like domains in the ext racellular region 
and contain short cytoplasmic regions with no known signaling motifs.  Binding of either PD-[ADDRESS_260463] notably on vascular 
endothelium, whereas PD-L2 protein is only detectably expressed on antigen- presenting cells 
found in lymphoid tissue or chronic inflammatory environments.  PD-L2 is thought to control immune T -cell activation in lymphoid o rgans, whereas PD-L1 serves to dampen unwarranted T-
cell fun ction in peripheral tissues.  Although healthy organs express little (if any) PD- L1, a 
variety of cancers were demonstrated to express abundant levels of this T- cell inhibitor.  PD -1 
has been suggested to regulate tumor- specific T -cell expansion in s ubjects with melanoma 
(MEL) .  This suggests that the PD-1/PD- L1 pathway plays a critical role in tumor immune 
evasion and should be considered as an attractive target for therapeutic intervention. 
Pembr olizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the 
IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-
L1 and PD-L2.  Keytruda
TM (pembrolizumab) has recently been approved in the United State s 
for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipi[INVESTIGATOR_77972], if BRAF V600 mutation positive, a BRAF inhibitor. 
4.1.3 Preclinical and Clinical Trial Data  
Refer to the Investigator’s Brochur e for Preclinical and Clinical data.  
Products:  Pembrolizumab/Trametinib   UCDCC#259  
  v.Original (05/09/2017)  
 
UC Davis Comprehensi ve Cancer Center  
Confidential   Page 12 of 87 4.2 Trametinib  
4.2.1 Background 
Refer to the Investigator’s Brochure (IB)/approved labeling for detailed background information 
on trametinib.  
4.2.2 Pharmaceutical and Therapeutic Background 
Trametinib is a reversible and highly selective allosteric inhibitor of mitogen -activated 
extracellular signal -regulated kinase ( MEK1  and MEK2 activation and kinase activity) . MEK 
proteins are critical components of the extracellular signal -regulated kinase (ERK) pathway 
which is commonly hyperactivated in tumor cells. Oncogenic mutations in both BRAF (a member of the RAF kinases) and RAS signal through MEK1 or MEK2.  
Trametinib is administered with doses up to [ADDRESS_260464] 1 hour prior to or 2 hours after a meal. 
Trametinib is being developed for the treatment of a variety of cancers and is currently approved 
in the [LOCATION_002], Canada, Australia, and the EU as a monotherapy treatment for the treatment of subjects with unr esectable or metastatic melanoma with BRAF V600 E/K mutation (approval 
was also granted in Chile on 22 September  2014). It is also approved in combination with 
dabrafenib for the same indication in the US and Australia. 
4.2.3 Preclinical and Clinical Trial Data  
Refer to the Investigator’s Brochure for Preclinical and Clinical data.  
4.[ADDRESS_260465] Population  
Recent advances such as targeted therapy with EGFR and  ALK tyrosine kinase inhibitors (TKIs) 
for patients harboring EGFR mutations and ALK translocations have dramatically improved 
patient outcomes and quality of life. However, no therapi[INVESTIGATOR_67668] K RAS , the most common 
oncogenic driver mutation i n NSCLC (~ 25%) are FDA approved. 
Discovery of new therapeutic combinations that can alter the natural history of K RAS  mutant 
lung cancer addresses a major unmet medical need.  
KRAS was the first oncogenic driver mutation identified in NSCLC patients over a quarter of a 
century ago . Ras is a GTP -binding membrane- associated protein that typi[INVESTIGATOR_216674]. Oncogenic K RAS  mutations lock  KRAS  in a 
persistently activated state that triggers three main downstream si gnaling pathways to varying 
degrees ( Ral, MEK/ERK and PI3K/AKT/MTOR) [1]. 
Products:  Pembrolizumab/Trametinib   UCDCC#259  
  v.Original (05/09/2017)  
 
UC Davis Comprehensi ve Cancer Center  
Confidential   Page [ADDRESS_260466] that combination therapy with MEK inhibitors can 
be a highly effective treatment option in advanced NSCLC. In particular, preclinical data suggests that taxanes such as docetaxel  are synergistic with MEK inhibitors  [2]  and in a 
randomized phase II clinical trial of 97 patients with K RAS  mutated lung cancer, patien ts who 
received the MEK inhibitor selumetinib with docetaxel versus patients who received docetaxel alone had a significant improvement in progression free survival (PFS) and a trend towards increased overall survival (OS) . In a recently presented single -arm phase I clinical trial from UC 
Davis and others at ASCO, a 28% response rate to docetaxel combined with the MEK inhibitor trametinib was observed in K RAS  mutant patients (single agent docetaxel response rates ~7%)9. 
A signal towards preferential activit y in KRAS  G12C mutant patients was observed (40% vs. 
20%), though sample size was small [3]. 
In several tumor types, in preclinical and translational studies the MEK -ERK pathway modulates 
PD-L1 expression, though different studies come to different conclusions regarding the degree 
and direction of this immunomodulation. In one preclinical study, PD-L1 expression is 
upregulated in melanoma cells resistant to BRAF inhibition and reversed by [CONTACT_216710]-L1 and induction of apoptosis [4] . 
In a rec ently published clinical study, patient samples with metastatic melanoma BRAF 
inhibition increased PD-L1 expression while also enhancing markers of T- cell toxicity and 
providing a more favorable tumor immune microenvironment [5]. In other tumor types, studies suggest PD-L1 is also dependent on MEK/ERK and suppressed by [CONTACT_216711]/ERK inhibition including Hodgkin’s and Non- Hodgkin’s Lymphoma  and restores anti -immune activity  [6]. 
Though there are somewhat discrepant conclusions regarding pre- clinical and 
clinical/translational data with MEKi and PD1/PDL1 inhibition in several tumor types, the weight of the evidence suggests that MEKi  can potentiate the immune response and modulate 
PD-L1 expression. In KRAS mutant NSCLC treatment with selumetinib led to upregulation of 
PD-1 on CD8 T-cells and depletion of Treg with increase in PD -1 and CTLA-4 providing some 
rationale for integrating PD -1 blockade with MEK inhibition and highlighting the need to biopsy 
tissue on treatment to examine the tumor immune microenvironment[7]. Examination of immune correlates in  tissue and blood in this early phase trial (including modulation of PD-L1 expression 
and T-cell subsets) are required to determine optimal sequencing of MEKi and PD1 antibody for maximum clinical impact.  
This proposal builds a foundation for the study of pembrolizumab ( MK-3475) with targeted 
therapeutic combinations incorporating MEK inhibitors in KRAS mutant NSCLC (a major unmet clinical need) and data regarding safety and tolerability from this proposal can be extended to other tumor types where MEK inhibition and PD1/PD-L1 blockade may be utilized. 
Higher response rates  with PD -[ADDRESS_260467] observed higher responses in NSCLC 
Products:  Pembrolizumab/Trametinib   UCDCC#259  
  v.Original (05/09/2017)  
 
UC Davis Comprehensi ve Cancer Center  
Confidential   Page 14 of 87 tumors with KRAS mutations (28% vs. 19%) suggesting potential roles for both KRAS and 
overall mutation burden in driving an adaptive immune escape phenotype (Fig ure 1). 
Figure 1. Response rates to pembrolizumab according to mutation status 
 
         Figure 2. In vivo antitumor activity in CT26 Mouse Model dependent on sequencing of MEK 
inhibition with trametinib and PD -1 blockade (Liu et al, Clinical Cancer Research 2015)  
 
 
 
 
Products:  Pembrolizumab/Trametinib   UCDCC#259  
  v.Original (05/09/2017)  
 
UC Davis Comprehensi ve Cancer Center  
Confidential   Page 15 of 87 Rationale for sequencing of combined therapy with MEK inhibitors and PD- 1/PD -L1 
blockade [8].  T he combination of trametinib  (a MEKi)  and anti- PD1 antibodies (RMP1-14 clone, 
rat IgG2a, Bioxcell)  was studied in the CT26 murine syngeneic tumor model, which is 
homozygous for  the KRAS  (G12D) mutation , and contains amplification of MAPK1 and MET 
genes,  in immune competent mice.  Thre e combination regimens were evaluated: (1) trametinib 
and anti-PD1 antibody given concurrently starting week; (2) trametinib in week 1  as a single  
agent with anti -PD-1 added in week 2; and (3) anti-PD-1 in week 1 with addition of trametinib in 
week 2 (Figure 2). All three combinatio ns were found to inhibit tumor growth more effectively 
than the single agent s during the initial 2 -3 weeks of treatment ( Figure 2). However, schedule 
mattered as the combination in which anti- PD-[ADDRESS_260468] on tumor growth ( Figure 2, C) . These findings reinforce the view that a detailed 
understanding of dose and schedule will likely have a profound impact on efficacy. Furthermore, 
the combination of trametinib and anti -PD-1 antibody increased tumor infiltrating CD8+ T cells 
in vivo compared to anti- PD-1 alone (data not shown), demonstrating the importance of 
concurrent immune monitoring for optimization of targeted therapy combinations.  Similar in 
vivo anti -tumor activity was observed in the CT26 model using a different  mouse anti- PD1 
antibody (mDX400), supporting the validity of the observations.  
4.3.2 Rationale for Dose Selection/Regimen/Modification  
An open- label Phase I trial (Protocol 001) is being conducted to evaluate the safety an d clinical 
activity of single agent pembrolizumab .  The dose escalation portion of this trial evaluated three 
dose levels, 1 mg/kg, 3 mg/kg, and 10 mg/kg, administered every 2 weeks (Q2W) in subjects with advanced solid tumors.  All three dose levels were well tolerated and no dose- limiting 
toxicities were observed.  This first in human study of pembrolizumab  showed evidence of target 
engagement and objective evidence of tumor size reduction at all dose levels (1 mg/kg, 3 mg/kg and 10 mg/kg Q2W).  No MTD has been identified to date.  10.0 mg/kg Q2W, the highest dose tested in PN001, will be the dose and schedule utilized in Cohorts A, B, C and D of this protocol to test for initial tumor activity.  Recent data from other clinical studies within the pembroliz umab  program has shown that a lower dose of pembrolizumab and a less frequent 
schedule may be sufficient for target engagement and clinical activity.  
PK data analysis of pembrolizumab  administered Q2W and Q3W showed slow systemic 
clearance, limited volume of distribution, and a long half- life (refer to IB).  Pharmacodynamic 
data (IL -2 release assay) suggested that peripheral target engagement is durable (>21 days).  This 
early PK and pharmacodynamic data provides scientific rationale for testing a Q2W and Q 3W 
dosing schedule.   
A population pharmacokinetic analysis has been performed using serum concentration time data 
from [ADDRESS_260469] a wide therapeutic range based on the 
melanoma indication.  The differences in exposure for a 200 mg fixed dose regimen relative to a 2 mg/kg Q3W body weight based regimen are anticipated to remain well within the established 
Products:  Pembrolizumab/Trametinib   UCDCC#259  
  v.Original (05/09/2017)  
 
UC Davis Comprehensi ve Cancer Center  
Confidential   Page 16 of 87 exposure margins of 0.5 – 5.0 for pembrolizumab in the melanoma indication. The exposure 
margins are based on the notion of similar efficacy and safety in melanoma at 10 mg/kg Q3W vs. 
the proposed dose regimen of 2 mg/kg Q3W (i.e. 5-fold higher dose and exposure). The population PK evaluation revealed that there was no significant impact of tumor burden on exposure. In addition, exposure was similar between the NSCLC and melanoma indications. Therefore, there are no anticipated changes in exposure between diff erent indication settings.  
The rationale for further exploration of 2 mg/kg and comparable doses of pembrolizumab in solid tumors is based on: 1) similar efficacy and safety of pembrolizumab when dosed at either 2 mg/kg or 10 mg/kg Q3W in melanoma patients, 2) the flat exposure-response relationships of pembrolizumab for both efficacy and safety in the dose ranges of 2 mg/kg Q3W to 10 mg/kg Q3W, 3) the lack of effect of tumor burden or indication on distribution behavior of pembrolizumab (as assessed by [CONTACT_78013]) and 4) the assumption that the dynamics of pembrolizumab target engagement will not vary meaningfully with tumor type.  
The choice of the 200 mg Q3W as an appropriate dose for the switch to fixed dosing is based on simulations performed using the population PK model of pembrolizumab showing that the fixed dose of 200 mg every 3 weeks will provide exposures that 1) are optim ally consistent with those 
obtained with the 2 mg/kg dose every 3 weeks, 2) will maintain individual patient exposures in the exposure range established in melanoma as associated with maximal efficacy response and 3) will maintain individual patients expos ure in the exposure range established in melanoma that 
are well tolerated and safe.  
A fixed dose regimen will simplify the dosing regimen to be more convenient for physicians and to reduce potential for dosing errors.  A fixed dosing scheme will also redu ce complexity in the 
logistical chain at treatment facilities and reduce wastage.  
The FDA approved starting dose of trametinib is 2 mg administered orally daily. This fixed dose of pembrolizumab is combined with trametinib starting a dose reduction of 1.5 mg daily and then escalated to trametinib 2 mg daily if the combination is well tolerated. Pembrolizumab is approved for the treatment of advanced NSCLC with positive PD-L1 expression. Intermittent 
and dose reduced schedule is designed  to manage potential toxicities seen in KEYNOTE -022 
trial in phase 1 dose escalation of continuous 2 mg of trametinib with pembrolizumab. Intermittent dosing also may be more favorable for reducing depletion of T-cells in response to prolonged MEK inhibition. 
4.3.3 Rationale for End points  
This is a phase I 3+3 dose escalation  study followed by [CONTACT_216712]. Therefore,  the endpoints include determination of MTD,  and recommended 
phase II dose (RP2D) correlative endpoints and secondary efficacy  endpoints. MTD and RP2D 
are standard  endpoints for phase I dose escalation  studies. 
• The recommended  dose expansion and recommended  phase II dose (RP2D) will be 
determined  by [CONTACT_216713].  
Products:  Pembrolizumab/Trametinib   UCDCC#259  
  v.Original (05/09/2017)  
 
UC Davis Comprehensi ve Cancer Center  
Confidential   Page 17 of 87 [IP_ADDRESS] Efficacy Endpoints 
• Overall  response rate (ORR).  ORR  is an acceptable measure of clinical  benefit  in 
early  phase clinical  trials  to provide a preliminary signal of activity  to consider later 
phase trials.  
• Progression- free survival  (PFS).  PFS is an acceptable measure of assessing  benefit in 
NSCLC  clinical  trials.  
As this is a phase I study,  our goal is a preliminary  assessment  of a signal  of efficacy as  defined  
in the statistical plan. 
[IP_ADDRESS] Biomarker Research  
[IP_ADDRESS].1 Immunology Correlates  
Immunology correlates will be performed by [CONTACT_216714] -
Oncology Laboratory Yale University and/or by [CONTACT_216715]. The Human Immune Monitoring Core at UC Davis is unde r 
the supervision of Emanual Maverakis, MD. [CONTACT_216783]’  laboratory  is  a  world  renowned  immunology  laboratory  and  has  the equipment and expertise to conduct the proposed studies. The Translational Immuno -Oncology Laboratory at Yale University is under the direction of 
David Rimm MD, Ph.D and Kurt Schalper, MD, Ph.D and has been a leader in the translational immuno -oncology of immune checkpoint inhibitors. 
a. Biopsy (Biopsy at Baseline, C1D11-13 and at progression (optional) 
• PD-L1 expression by [CONTACT_216716]-L1 expression  in response to treatment  will be conducted by 
[CONTACT_216717] -Oncology under the direction of Kurt Schalper using the approved DAKO 
22C3 antibody and in a ddition quantitative IHC assays for PD -L1 if tissue permits. UC 
Davis may also perform IHC for PD -L1 using the standard DAKO 22C3 antibody. 
• Enumeration and changes  in immune cell subsets by [CONTACT_216718]- Oncology. 
• Whole exome DNA/RNA next generation sequencing and assessment of mutational load will be performed by [CONTACT_216719]. The Broad Institute is a world leader in genomic sequencing and analysis. 
• Tissue banked for RPPA (Reverse Phase Protein Assays) for on -target EGFR pathway 
inhibition will be performed by [CONTACT_216720].  
 
Products:  Pembrolizumab/Trametinib   UCDCC#259  
  v.Original (05/09/2017)  
 
UC Davis Comprehensi ve Cancer Center  
Confidential   Page 18 of 87 b. Plasma PD -L1 DNA/RNA levels will be assayed by [CONTACT_216721] a CLIA certified 
laboratory. 
Additional peripheral  blood will be collected  and banked at  relevant  time points for enumeration 
of immune  cell subsets  and changes  in cytokine expression in response to treatment with  
methods including Flow Cytometry  and Luminex Cytokine Assays by [CONTACT_216722].  
[IP_ADDRESS].2 Molecular Correlates  
a. Biopsy 
Whole exome DNA/RNA next generation sequencing  including KRAS aminio acid substitution, 
p53 and LKB1 mutations, and assessment of mutational load will be performed by [CONTACT_216723]. The Broad Institute is a world leader in genomic sequencing and analysis. 
b. Plasma KRAS -mutant DNA/RNA Levels  
Changes  in plasma  KRAS -mutant DNA/RNA in patients  with KRAS -mutant NSCLC  may be 
prognostic for recurrence,  the development of resistance to existing  therapi[INVESTIGATOR_216675].  Determination of plasma  KRAS -mutant 
DNA/RNA levels  will be conducted at Liquid Genomics in a CLIA certified laboratory.  
c. If tissue permits, analysis for pharmacodynamic markers of on- target MEK -ERK inhibition 
with RPPA will be performed by [CONTACT_216724].  
 
5.0 METHODOLOGY  
5.1 Entry Criteria  
5.1.1 Diagnosis/Condition for Entry into the Trial 
Stage IV or Metastatic/Recurrent Non -Small Cell Lung Cancer. For expansion cohorts, patient’s 
tumor must also harbor a KRAS mutation detected in a CLIA certified laboratory . 
5.1.[ADDRESS_260470]: 
1. Have histologically or cytologically confirmed non- small cell lung cancer.  
2. Have stage IV, metastatic or recurrent non-squamous NSCLC with progressive disease 
after platinum containing chemotherapy (EGFR mutant, ALK, or ROS- [ADDRESS_260471] progressed on prior approved TKI’s). 
Products:  Pembrolizumab/Trametinib   UCDCC#259  
  v.Original (05/09/2017)  
 
UC Davis Comprehensi ve Cancer Center  
Confidential   Page 19 of 87 3. For phase I dose expansion cohorts the patient’s tumor must harbor a KRAS mutation 
detected by a CLIA certified laboratory.  
4. Be willing and able to provide written informed consent/assent for the trial. 
5. Be ≥ [ADDRESS_260472] systemic treatment , within 6 months of signing consent and that tissue is available for either 2 cell 
blocks or 20 uncut slides (core or excisional biopsy required, fine needle aspi[INVESTIGATOR_216676]) . 
8. Have a performance status of [ADDRESS_260473] any 
clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels. 
10. Demonstrate adequate organ function as defined in Table 1 , all screening labs should be 
performed within 10 days of treatment initiation.    
Table 1.  Adequate Organ Function Laboratory Values 
System  Laboratory  Values  
Absolute neutrophil count  ≥1.5 × 109/L 
Hemoglobin  ≥9 g/dL  
Platelets  ≥100 × 109/L   
PT/INR and PTT  ≤1.[ADDRESS_260474]  
Hepatic  
Albumin  ≥2.5 g/dL  
Total bilirubin  ≤1.[ADDRESS_260475] and ALT  ≤ 2.5× ULN  
Renal  
Creatinine or  ≤ 1.[ADDRESS_260476]  
Calculated creatinine clearancea  ≥ 50 mL/min  
Cardiac  
Left Ventricular Ejection fraction (LVEF)  ≥ LLN by [CONTACT_216725]=alanine aminotransferase; AST= aspartate amino transferase; INR= international normalized ratio;  
PT=prothrombin time; PTT= partial thromboplastin time; ULN=upper limit of normal; LLN=lower limit of 
normal  
a  Calculated by [CONTACT_16424] -Gault formula .  
b  Same method as used at baseline must be use throughout the study, ECHO is the preferred method  
 
Products:  Pembrolizumab/Trametinib   UCDCC#259  
  v.Original (05/09/2017)  
 
UC Davis Comprehensi ve Cancer Center  
Confidential   Page [ADDRESS_260477] will be required.    
12. Female subjects of child bearing potential (Section 5.8.2) must be willing  to use an 
adequate method of contraception as outlined in Section 5.8.2 – Contraception, for the course of the study through [ADDRESS_260478] dose of study medication. Note: Abstinence is acceptable if this is the usual lifestyle and preferred cont raception for 
the subject.  
 
13. Male subjects of childbearing potential (Section 5.8.1) must agree to use an adequate method of contraception as outlined in Section 5.8.1- Contraception, starting with the first dose of study therapy through [ADDRESS_260479] dose of study therapy. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.  
 
5.1.[ADDRESS_260480]:  
1. Is currently par ticipating and receiving study therapy or has participated in a study of an 
investigational agent and received study therapy  or used an investigational device within 
[ADDRESS_260481] dose of trial treatment.   Inhaled or topi[INVESTIGATOR_14271].  
3. Has a known history of active TB   (Bacillus Tuberculosis). 
4. Hypers ensitivity to pembrolizumab or any of its excipi[INVESTIGATOR_840].  
5. Has had a prior anti -cancer monoclonal antibody (mAb) within 3 weeks prior to study 
Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to agents administered more than 3 weeks earlier.  
6. Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent. 
- Note:  Subjects with ≤ Grade 2 neuropathy or alopecia are an exception to this 
criterion and may qualify for the study. 
- Note:  If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.   
Products:  Pembrolizumab/Trametinib   UCDCC#259  
  v.Original (05/09/2017)  
 
UC Davis Comprehensi ve Cancer Center  
Confidential   Page 21 of 87 7. Has a known additional malignancy that is progressing or requires active treatment.  
Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.  
8. Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.  Subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by [CONTACT_216726]), have no evidence of new or enlarging brain metastases, and are not using steroids for at least [ADDRESS_260482] 2 years 
(i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pi[INVESTIGATOR_13002], etc.) is not considered a form of systemic treatment.  
10. Has known history of, or any evidence of active, non-infectious pneumonitis. History of radiation pneumonitis is allowed provided that it is not active and no corticosteroids were required for pneumonitis management. 
11. Evidence of interstitial lung disease . 
12. Has an active infection requiring system ic therapy.  
13. Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy  to drugs 
chemically related to trametinib, or excipi[INVESTIGATOR_216677] (DMSO) . 
14. History of retinal vein occlusion (RVO). 
15. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject’s participation for the full duration of the trial, or is not in the best interest of the subjec t to participate, in 
the opi[INVESTIGATOR_80021].   
16. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.  
17. Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through [ADDRESS_260483] dose of trial treatment.  
18. Has received prior therapy with an anti -PD-1, anti- PD-L1, or anti- PD-L2 agent  for dose 
expansion. (Patients in dose escalation may have received an anti -PD-1, anti -PD-L1, or 
anti-PD-L2 agent ). 
19. Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies). 
20. Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV R NA 
[qualitative] is detected).  
21. History or evidence of cardiovascular risk including any of the following: 
Products:  Pembrolizumab/Trametinib   UCDCC#259  
  v.Original (05/09/2017)  
 
UC Davis Comprehensi ve Cancer Center  
Confidential   Page 22 of 87 •  LVEF< LLN on screening exam.  
• A QT interval corrected for heart rate using the Fridericia’s formula (QTc F; 
Appendix X ) ≥470 msec (Appendix 11.2) on scr eening exam.  
• History or evidence of current clinically significant uncontrolled arrhythmias. 
• Clarification : Subjects with atrial fibrillation controlled for  >30 days prior to 
dosing are eligible. 
• History of acute coronary syndromes (including myocardial infarction and 
unstable angina), coronary angioplasty, or stenting within 6 months prior to 
enrollment. 
• History or evidence of current ≥ Class II congestive heart failure as defined by 
[CONTACT_216727] t Association  (NYHA;  Appendix 11.5).  
• Treatment refractory hypertension defined as a blood pressure of systolic> 140 
mmHg and/or diastolic > 90 mm Hg which cannot be controlled by [CONTACT_14181]-hypertensive therapy;  
• Patients with intra -cardiac defibrillators.  
22. Has received a live vaccine within 30 days of planned start of study therapy. 
 Note:  Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu -Mist®) are live attenuated 
vaccines, and are not allowed.  
 
5.2 Trial Treatments  
The treatment to be used in this trial is outlined below in Table 2.  
Table 2.  Trial Treatment s 
Drug  Dose/Potency  Dose 
Frequency  Route of 
Administration  Regimen/Treatment 
Period  Use 
Pembrolizumab  
(MK -3475)  200 mg Q3W  IV infusion  Day 1  
of each 3 week cycle  Experimental  
Trametinib  x mg † Daily † PO Daily starting D1  Experimental  
† See dose escalation schema. RP2D for expansion cohorts.  
 Dose Escalation Cohort (Arm A): Trametinib will be adminstered starting C1D1  and continued 
as per Table 3,  until determination of the MTD .  Pembrolizumab will be added to trametinib 
starting C2D1.  
Products:  Pembrolizumab/Trametinib   UCDCC#259  
  v.Original (05/09/2017)  
 
UC Davis Comprehensi ve Cancer Center  
Confidential   Page 23 of 87 Dose Escalation Cohort (Arm B): Pembrolizumab will be administered starting C1D1 and 
trametinib will be added to pembrolizumab starting C2D1.   
Expansion Cohort (Arm) A: Trametinib will be administered starting C1D1 and pembrolizumab 
will be added to trametinib starting C2D1 at the MTD of the combination as determined from the 
dose escalation portion of the study.   
Expansion Cohort (Arm) B: Pembrolizumab will be administered starting C1D1 and trametinib 
will be added to pembrolizumab starting C2D1 at the MTD of the combination as determined 
from the dose escalation portion of the study.   
5.2.1 Dose Selection/Modification  
[IP_ADDRESS] Dose Selection  
The rationale for selection of doses to be used in this trial is provided in Section 4.0 – 
Background and Rationale.   
The dose of pembrolizumab is fixed at 200 mg IV Q3W.  
The dose escalation schema of trametinib is as follows. Each cycle is Q3W  (21 days). 
Table 3. Dose Escalation Schema for Trametinib  
Dose Level  Trametinib dose  
(PO Daily)  Q3W  Pembrolizumab (MK -3475) dose IV Q3W  
-1 1.5 mg (D1 -D7) 200 mg  
*1 1.5 mg  (D1-D10)  200 mg  
2 2.0 mg  (D1-D10)  200 mg  
* Dose level 1 is the starting dose. For each cohort , trametinib dose will be the same for lead in and fo r concurrent 
trametinib + pembrolizumab administration.  
 For Cohort A: Lead in trametinib will precede combination trametinib and pembrolizumab, 
which will commence for C2.  
For Cohort B: Lead in pembrolizumab will precede combination trametinib and pembrolizumab, which will commence for C2.  
The recommended dose expansion and recommended phase II dose (RP2D) will be determined by [CONTACT_216728]  (the maximum dose level where [ADDRESS_260484] been 
treated in the dose escalation portion of the study) and toxicities observed in the dose escalation portion of this study. 
Products:  Pembrolizumab/Trametinib   UCDCC#259  
  v.Original (05/09/2017)  
 
UC Davis Comprehensi ve Cancer Center  
Confidential   Page 24 of 87 [IP_ADDRESS] Dose Modification (Escalation/Titration/Other)  
Adverse events (both non-serious and serious) associated with pembrolizumab exposure may 
represent an immunologic etiology.  These adverse events may occur shortly after the first dose or several months after the last dose of treatment.  Pembrolizumab must be withheld for drug -
related  toxicities  and severe or life- threatening AEs as per  Table 5  below. See dose modification 
and supportive care guideline sections , including use of corticosteroids. There are no dose 
reductions for pembrolizumab. 
Dosing interruptions are permitted in th e case of medical/surgical events or logistical reasons not 
related to study therapy  (e.g., elective surgery, unrelated medical events, patient vacation, and/or 
holidays). Subjects should be placed back on study therapy within 3 weeks of the scheduled 
interruption. The reason for interruption should be documented in the patient's medical  record.  
Table 4. Dose Modification for Trametinib. Lowest permitted Trametinib dose will be 1 .5 mg 
daily.  
 
Table 5. Dose Modification Guidelines for Pembrolizumab (MK-3475) for Drug -Related 
Adverse Events  
Toxicity  Hold 
Treatment 
For Grade Timing for Restarting 
Treatment  Treatment Discontinuation  
Diarrhea /Colitis  2-[ADDRESS_260485] dose  
3-4 Permanently discontinue  
(see exception below)a Permanently discontinue  
Type 1 diabetes 
mellitus (if new 
onset) or T1DM or  
3-4 Hold pembrolizumab for new 
onset Type 1 diabetes mellitus or 
Grade 3 -4 hyperglycemia Resume pembrolizumab when patients are clinically 
and metabolically stable  Dose Level  Trametinib Dose (QD)   
(D1-D10 administration unless otherwise specified)  
For Starting Dose  2 mg  1.5 mg 1.5 mg (dosed 
from D1 -D7) 
1st Does Reduction  1.5 mg 1.5 mg (dosed from D1 -D7) Discontinue 
Trametinib  
2nd Dose Reduction  1.5 mg  
(dosed from D1- D7) Discontinue trametinib  - 
Products:  Pembrolizumab/Trametinib   UCDCC#259  
  v.Original (05/09/2017)  
 
UC Davis Comprehensi ve Cancer Center  
Confidential   Page [ADDRESS_260486] dose 
or inability to reduce corticosteroid to 10 mg or less of 
prednisone or equivalent per day within 12 weeks  
4 Permanently discontinue  Permanently discontinue  
Note: Permanently discontinue for any severe or Grade [ADDRESS_260487] or ALT increases by [CONTACT_216729] 50% relative to baseline and lasts for at least 1 week then patients should be discontinued.  
b  If symptoms resolve within one hour of stoppi[INVESTIGATOR_13056], the infusion may be restarted at 50% of the original infusi on 
rate   (e.g., from 100 mL/hr to 50 mL/hr).  Otherwise dosing will be held until symptoms resolve and the subject should be premedicated for the next scheduled dose; Refer to  Table 3 – Infusion Treatment Guidelines for further management 
details.  
c  Patients with intolerable or persistent Grade [ADDRESS_260488] be at an equivalent dose of  ≤10mg 
per day of prednisone to resume dosing with pembrolizumab. Furthermore, an inability to reduce 
Products:  Pembrolizumab/Trametinib   UCDCC#259  
  v.Original (05/09/2017)  
 
UC Davis Comprehensi ve Cancer Center  
Confidential   Page 26 of 87 the corticosteroid dose for managing a drug- related adverse event to the equivalent of ≤[ADDRESS_260489] pembrolizumab  dose should result in permanent 
discontinuation from pembrolizumab. With investigator and Sponsor Investigator agreement, 
subjects with a laboratory adverse event still at Grade 2 after 12 weeks may continue treatment in 
the trial only if asymptomatic and controlled. For information on the management of adverse events, see Section 5.7.2. 
In subjects who continue on pembrolizumab having experienced a Grade 3, Grade 4, or 
persistent  (> 4 weeks) Grade [ADDRESS_260490] has recovered from the AE to 
Grade 0-1, the dosing interval in subsequent cycles may be increased by 1 week (e.g., to every 4 week dosing in subjects who were on an every 3 week schedule). However, in subjects who experience Grade 3 or 4 pneumonitis, or recurrent persistent (>4 weeks) Grade 2 drug - related 
pneumonitis after rechallenge from a prior epi[INVESTIGATOR_216678] (> 4 weeks)Grade [ADDRESS_260491] be permanently discontinued. 
For subjects who experience a recurrence of the same AE(s) at the same grade or greater with  
rechallenge of pembrolizumab , a consultation between the Sponsor Investigator  and investigator 
should occur to determine whether the subject should continue in the trial. However, for a subject who experiences a recurrence of the same serious adverse event at the same grade or greater  with rechallenge of pembrolizumab, the subject must discontinue pembrolizumab. 
Table 6 Dose Mo dification Guidelines for Trametinib for Drug- Related Adverse Events  (Unless 
Otherwise Specified)  
Grade  (CTC -AE)*  Dose Modifications  
Grade 1 or Grade 2  (Tolerable)  Continue treatment and monitor as clinically  indicated.  
Grade 2 (Intolerable) or Grade  3 Interrupt  therapy  until toxicity  is grade  0-1 and  reduce  by [CONTACT_216730].  
Grade  4 Discontinue  permanently,  or interrupt  therapy  until Grade  0 to 1 and 
reduce by [CONTACT_216731].  
 
Please follow Table 5 and Table 6 for dose modifications unless specified below. 
For Grade ≥ 3 drug related adverse events attributed to trametinib both pembrolizumab and 
trametinib should be simultaneously interrupted with the exceptions shown  below. Except for Grade ≥ 3 lymphopenia 
Exceptions where dose modifications are necessary for only trametinib: 
• LVEF  reduction 
• Retinal Vein Occlusion (RVO) and Retinal Pi[INVESTIGATOR_216679] (RPED)  
Products:  Pembrolizumab/Trametinib   UCDCC#259  
  v.Original (05/09/2017)  
 
UC Davis Comprehensi ve Cancer Center  
Confidential   Page 27 of 87  
Table 7. Trametinib Dose Modification Guidelines and Stoppi[INVESTIGATOR_216680] -drop (%)  or 
CTCAE  grade  Action and Dose  Modification 
Asymptomatic  Absolute decrease of  >10%  
in LVEF compared  to 
baseline and  ejection  fraction 
below  the institution’s  LLN.  • Interrupt trametinib  and repeat ECHO/ MUGA  within  2 
weeks .a 
• If the LVEF recovers within 4 weeks (defined as LVEF  
≥LLN and absolute  decrease  
≤10% compared to baseline):  
– Consult with the [COMPANY_001]  trametinib medical monitor and 
request approval for restart.  
– Restart treatment  with trametinib at reduced  dose by [CONTACT_23615].  
– Repeat ECHO/MUGA 2, 4, 8, and 12 weeks after  re- 
start; continue in  intervals  of 12 weeks  thereafter.  
• If LVEF does not  recover  within 4  weeks:  
– Consult with  cardiologist.  
– Permanently  discontinue  trametinib.  
– Report as SAE  
– Repeat ECHO after 2, 4, 8, 12, and 16 weeks  or until 
resolution.  
Symptomati cb • Grade 3: resting LVEF  
39-20% or >20%  absolute  
reduction from  baseline  
• Grade 4:  
Resting  LVEF  ≤20%.  • Permanently  discontinue  trametinib.  
• Report as SAE.  
• Consult with cardiologist.  
• Repeat ECHO/MUGA after  2, 4, 8, 12, and 16 weeks  or 
until resolution.  
a If ECHO/MUGA does not show LVEF recovery after 2 weeks,  repeat  ECHO/MUGA 2 weeks  later.  
b Symptoms may include: dyspnea, orthopenea, and other signs and  symptoms  of pulmonary congestion and  edema. 
 
 
  
Products:  Pembrolizumab/Trametinib   UCDCC#259  
  v.Original (05/09/2017)  
 
UC Davis Comprehensi ve Cancer Center  
Confidential   Page 28 of 87 Table 8. Trametinib Withholding and Stoppi[INVESTIGATOR_190727]*  Action and Dose Modification 
• QTc ≥501 msec, or  
• Uncorrected QT >600 msec, or  
• QTc >530 msec for subjects  with bundle branch 
block  • Interrupt study treatment until QTc  prolongation resolves to 
grade 1 or baseline.  
• Test serum potassium, calcium, phosphorus, and 
magnesium. If abnormal, correct per routine clinical practice to within normal limits.  
• If the QTc prol ongation resolves to grade [ADDRESS_260492] will benefit from further 
treatment.  
• If the event does not resolve, permanently discontinue 
study treatment.  
• If the event recurs,  permanently  discontinue study 
treatment.  
Abbreviations:  msec = milliseconds; QTc = QT interval on electrocardiogram  
*  Based on average QTcF value of triplicate ECGs. For example, if an ECG demonstrates a prolonged QT interval, obtain two or 
more ECGs over a brief period, and then use the averaged QTcF values of the three ECGs to determine if study treatments 
should be interrupted or discontin ued. (See Appendix 11. 4 for QTcF calculation).  
 
Table 9. Trametinib Dose Modification Guidelines for Hypertension 
Toxicity  Grade  Dose Modification  
2: Asymptomatic  Maintain dose level  
3: Asymptomatic  Hold until blood pressure is well controlled. Restart at reduced dose level.  
3: Symptomatic  Hold until blood pressure is well controlled. Restart at reduced dose level.  
[ADDRESS_260493] been observed in patients receiving trametinib, and can be  caused by [CONTACT_216732] (CSR) with retinal pi[INVESTIGATOR_216681] (RPED), or Retinal Vein 
Occlusion (RVO). Patients are required  to have a standard ophthalmic exam performed by [CONTACT_216733]. The  exam  will 
include indirect  fundoscopic examination, visual acuity (corrected), visual field examination,  
tonometry, and  direct  fundoscopy. Special  attention  should be given  to retinal  (e.g., CSR, RPED) 
or retinal vein abnormalities (e.g., RVO).  
  
Products:  Pembrolizumab/Trametinib   UCDCC#259  
  v.Original (05/09/2017)  
 
UC Davis Comprehensi ve Cancer Center  
Confidential   Page 29 of 87 Table 10. Management and Trametinib  Dose Modification for Visual Changes and/or 
Ophthalmic Examination Findings  
Event  CTCAE  
Grade  Management  
Guideline  Dose  Modification  
Grade  1* • Consult  
ophthalmologist  
within 7 days  of 
onset.  • If dilated fundus examination cannot  be performed within [ADDRESS_260494]/ophthalmologist.  
• If RPED and RVO  excluded,  continue/or restart trametinib  at same 
dose level.  
• If RPED suspected/diagnosed: See RPED dose modification table  
below  (following this table); report as  SAE . 
• If RVO diagnosed : Permanently  discontinue trametinib and 
report  as SAE.  
Grade 2  and 
Grade  3 • Consult  
ophthalmologist  
immediately.  • Hold trametinib  
• If RPED or RVO excluded,  restart  trametinib at same dose level  
after visual AE is < grade 1.  If  no recovery within 3 weeks, 
discontinue  trametinib  
• If RPED diagnosed : See  RPED  dose modification table  below;  
report as  SAE . 
• If RVO : Permanently  discontinue  trametinib and report as 
SAE.  
Grade  4 • Consult  
ophthalmologist  
immediately.  
• Report as  SAE.  • Hold Trametinib  
• If RPED/RVO excluded, may  restart  trametinib at same or reduced  
dose after discussion with the  Principal Investigator  
• If RVO or RPED,  permanently  discontinue  trametinib.  
Abbreviations: R PED= retinal pi[INVESTIGATOR_216682]; RVO =retinal  vein occlusion; SAE= serious adverse  event  
* If visual changes are clearly unrelated to study treatment (e.g.,  allergic  conjunctivitis), monitor closely but ophthalmic 
examination is not  required.  
 
Table 11. Trametinib Dose Modification for RPED 
Event  CTCAE  Grade  Action and Dose  Modification 
Grade 1 RPED  (Asymptomatic;  
clinical or  diagnostic  observations  only)  • Continue treatment with retinal  evaluation  monthly until resolution. 
If RPED  worsens,  follow instructions  below.  
Grade 2 -3 RPED  (Symptomatic  with 
mild to moderate  decrease  in visual 
acuity; limiting  instrumental ADL)  • Interrupt trametinib.  
• Retinal evaluation  monthly.  
• If improved to ≤ Grade 1, restart  trametinib  with one dose level 
reduction (reduced  by 
• 0.5 mg) or discontinue in patients  taking  trametinib 1 mg  daily.  
• If no recovery within 4 weeks  permanently  discontinue  trametinib  
 
Products:  Pembrolizumab/Trametinib   UCDCC#259  
  v.Original (05/09/2017)  
 
UC Davis Comprehensi ve Cancer Center  
Confidential   Page 30 of 87 Table 12. Management and Dose Modification Guidelines for Diarrhea 
 
  CTCAE Grade  Adverse Event Management  Action and Dose Modification 
Uncomplicated 
Diarrhea,1 
Grade 1 or  2 • Diet: Stop all  lactose containing products;  eat small 
meals,  BRAT -diet (banana, rice,  apples, toast)  
recommended.  
• Hydration: 8-10 large glasses of clear  liquids per day 
(e.g., Gatorade or broth).  
• Loperamide3: Initially  4 mg, followed by 2 mg every 4 
hours or  after every unformed  stool; maximum 16 
mg/day. Continue until  diarrhea- free for 12  hours.  
• Diarrhea >24  hours : Loperamide 2 mg every  2 hours; 
maximum  16 mg/day. Consider  adding oral antibiotics.  
• Diarrhea >48  hours : Loperamide 2 mg every  2 hours; 
maximum  16 mg/day. Add budesonide or other  second -
line th erapi[INVESTIGATOR_014] (otreotide,  or tincture of opi[INVESTIGATOR_1890]) and oral 
antibiotics.  • Continue trametinib.  
• If diarrhea is grade 2 for > 48h,  
interrupt trametinib until 
diarrhea resolves to grade ≤1. 
• Restart trametinib at the same  
dose level  
• If treatment delay is > 28  days, 
discontinue trametinib.  
Uncomplicated 
Diarrhea,1 
Grade 3 or 4  
 
Any 
Complicated Diarrhea2  • Clinical  evaluation mandatory.  
• Loperamide3: Initially  4 mg, followed by 2  mg every 4 
hours or  after every unformed  stool; maximum 16 
mg/day. Continue until  diarrhea- free for 12  hours.  
• Oral antibiotics  and second -line therapi[INVESTIGATOR_216683]  
• Hydration: Intravenous fluids if clinically indicated.  
• Antibiotics (oral  or intravenous) if clinically indicated.  
• Intervention should  be continued until the  subject is 
diarrhea- free for  ≥24 hours.  
• Intervention may  require  hospi[INVESTIGATOR_216684] - threatening  complications.  • Interrupt trametinib and 
pembrolizumab until  diarrhea 
resolves to ≤  grade  1. Then  
restart pembrolizumab and trametinib reduced  by [CONTACT_216734].
4 
• If 3 dose reductions of  study 
treatment are clinically  
indicated, permanently  
discontinue trametinib . 
• If treatment delay is >28  days, 
discontinue trametinib and pembrolizumab.  
1 Uncomplicated diarrhea defined by [CONTACT_216735][INVESTIGATOR_007], nausea/vomiting, ≥ grade 2, decreased 
performance status, pyrexia,  sepsis, neutropenia  ≥ grade  3, frank  bleeding,  and/or  dehydration  requiring intravenous  fluid 
substitution.  
2 Complicated diarrhea defined by [CONTACT_216736][INVESTIGATOR_007], nausea/vomiting, ≥ grade 2, decreased 
performance status, pyrexia,  sepsis, neutropenia  ≥ grade  3, frank  bleeding,  and/or  dehydration  requiring intravenous  fluid 
substitution. Patients with complicated diarrhea should be evaluated for pembrolizumab mediated autoimmune colitis with 
additional management as specified for pembrolizumab.  
[ADDRESS_260495] 
signs of  diarrhea.  
4 Escalation of  trametinib to previous dose level is allowed after consultation with  the study chair and in the absence of another 
epi[INVESTIGATOR_190721] 4 weeks subsequent to dose  reduction.  
Products:  Pembrolizumab/Trametinib   UCDCC#259  
  v.Original (05/09/2017)  
 
UC Davis Comprehensi ve Cancer Center  
Confidential   Page 31 of 87 Table 13. Dose Modification Guidelines and Management for Rash 
Rash  
Severity  Management  Guideline  Dose  Modification  
Grade 1  • Initiate prophylactic and  
symptomatic treatment measures.1 
• Use moderate strength topi[INVESTIGATOR_159811].2 
• Reassess after 2 weeks.  • Continue trametinib.  
• If rash does not recover to baseline within [ADDRESS_260496] supportive care, reduce trametinib by 
[CONTACT_28633] .3 
Grade 2  • Initiate prophylactic and 
symptomatic treatment measures.1 
• Use moderate strength topi[INVESTIGATOR_159811].2 
• Reassess after 2 weeks.  • Reduce trametinib by [CONTACT_30560].  
• If rash recovers to ≤ grade 1 within 2 weeks, increase dose to previous dose level.  
• If no recovery to ≤ grade 1 within 2 weeks, interrupt trametinib until recovery to ≤ grade 1.  
• Restart trametinib at reduced dose level.  
Grade ≥3  • Use moderate strength topi[INVESTIGATOR_28709] . Consider oral methyl -
prednisolone dose pack.2 
• Consider c onsult ing dermatologist.  • Interrupt trametinib until rash recovers to ≤ grade 1.  
Then restart pembrolizumab and trametinib  (reduced 
by [CONTACT_30560] ).3 
• If no recovery to ≤ grade [ADDRESS_260497] 6 weeks of study  treatment.  
2 Moderate-strength topi[INVESTIGATOR_8826]: Hydrocortisone 2.5% cream or  fluticasone  priopi[INVESTIGATOR_16847] 0.5%  cream.  
3 Trametinib may be escalated to previous dose level if no rash is evident    4 weeks after restarting study  treatment.  
 
      
  
Products:  Pembrolizumab/Trametinib   UCDCC#259  
  v.Original (05/09/2017)  
 
UC Davis Comprehensi ve Cancer Center  
Confidential   Page 32 of 87 Table 14. Pneumonitis Guidelines 
CTCAE  
Grade  Adverse Event  Management  Action and Dose  Modification 
Grade  1 • CT scan (high -resolution with  lung windows)  
recommended.  
• Work -up for  infection.  
• Monitoring of oxygenation via  pulse - oximetry  
recommended.  
• Consultation with pulmonologist  recommended.  • Continue  trametinib  at current  dose.  
Grade  2 • CT scan (high -resolution with  lung windows).  
• Work -up for  infection.  
• Consult  pulmonologist.  
• Pulmonary function tests: If <  normal, repeat 
every 8 weeks until  ≥ normal.  
• Bronchoscopy with biopsy  and/or  BAL  
recommended.  
• Symptomatic therapy  including  corticosteroids if 
clinically  indicated.  • Interrupt  trametinib  and pembrolizumab  
until recovery  to grade  ≤1. 
• If AE resolved  to Grade ≤1  and 
relationship to  trametinib  and or 
pembrolizumab is equivocal,  restarting  
pembrolizumab and trametinib (with 
dose reduction at investigators 
discretion) may be considered,  after 
discussion with  the study  chair.  
• If treatment delay  is > 4 weeks,  
permanently  discontinue  trametinib  and 
pembrolizumab. 
Grade  3 • CT scan (high -resolution with  lung windows).  
• Work -up for infection.  
• Consult  pulmonologist.  
• Pulmonary function tests -if < normal,  repeat every 
8 weeks until ≥  normal.  
• Bronchoscopy with biopsy  and/or  BAL if  
possible.  
• Symptomatic therapy  including corticosteroids as 
clinically  indicated.  • Permanently  discontinue  trametinib  and 
pembrolizumab. 
Grade  4 • Same as grade  3. • Permanently  discontinue  trametinib  and 
pembrolizumab. 
Abbreviations:  BAL = bronchoalveolar lavage; CT = computed  tomography.  
 
Dose Reduction Scheme for Trametinib   
No dose reductions for trametinib are permitted below 1 .5 mg PO daily.  
  
Products:  Pembrolizumab/Trametinib   UCDCC#259  
  v.Original (05/09/2017)  
 
UC Davis Comprehensi ve Cancer Center  
Confidential   Page 33 of 87 5.2.2 Timing of Dose Administration 
Trial treatment should be administered on Day 1 of each cycle after all procedures/assessments 
have been completed as detailed on the Study Calendar  (Section 6.0).  Trial t reatment may be 
administered up to 3 days before or after the scheduled Day 1 of each cycle due to administrative reasons.  
All trial treatments will be administered on an outpatient basis.  
Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks.  Sites should make every effort to target infusion timing to be as close to 30 minutes as possible.  However, given the variability of infusion pumps from site to site, a window of -5 minutes and +10 minutes is permitted (i.e., infusion ti me is 30 minutes: -5 min/+10 min).  
5.3 Treatment  
The dose escalation portion of the trial will determine the MTD. Once the dose escalation portion is complete, patients will enroll sequentially  (see Statistic al Analysis  Plan section for further 
details)  into one of two  expansion cohorts as noted below.   Enrollment into Expansion Cohorts 
A and B are pre-planned in regards to sequence and timing. Arm A (l ead in trametinib) will open 
first to dose escalation and will accrue 3 patients. Once 3 patients are accrued for Arm A, Arm B 
will open and accrue 3 patients. 
 
5.4 Definition of Dose Limiting Toxicities  
All toxicities will be graded using National Cancer Institute (NCI) CTCAE Version 4.0. The 
occurrence of any of the following toxicities during the first two cycles (i.e. after completion of 
the lead in cycle and the first cycle where both pembrolizumab and trametinib are administered)  
will be considered a DLT, if judged by [CONTACT_110515], probably or definitely 
related to study drug administration . The goal of the dose escalation portion of the study is to 
assess the safety of the combination after pembrolizumab or trametinib lead in, therefore, patients must have completed the lead in phase and also have received both trametinib and pembrolizumab con currently  to be evaluable for a DLT.  
A DLT evaluable subject is defined as a subject who receives treatment for the 6 week dose-
limiting  toxicity (DLT) observation per iod and who receives at least 80 % of all planned 
treatments.  A subject who does not recei ve at least 80% of planned treatment due to AEs that are 
unrelated to study treatment will not be considered evaluable for DLTs and may be replaced  as Expansion 
Cohort (Arm)  Regimen  Number of patients  
A Lead in trametinib for 1 cycle (Q3W) followed by 
[CONTACT_216737].  12 
B Lead in pembrolizumab for 1 cycle (Q3W) followed by 
[CONTACT_216737].  12 
Products:  Pembrolizumab/Trametinib   UCDCC#259  
  v.Original (05/09/2017)  
 
UC Davis Comprehensi ve Cancer Center  
Confidential   Page [ADDRESS_260498] subjects who are not evaluable for DLT or to ensure a thorough evaluation of a given dose level during the dose escalation part of the study. An event will be considered a dose- limiting toxicity (DLT) if it occurs during the  first two cycle s of 
treatment (first 6 weeks after initiating treatment) and meets at least one of the  following criteria : 
• Clinically significant hematologic toxicity (e.g. grade 4 neutropenia lasting more than 
7 days or accompanied by [CONTACT_216738], or Grade 4 thrombocytopenia of any 
duration)   
• Clinically significant Grade ≥3 non-hematologic toxicity that has not been previously 
identified for either pembrolizumab or dabrafenib/trametinib and cannot be controlled 
with routine supporti ve measures (e.g . anti- emetics)  
• Clinically significant Grade ≥[ADDRESS_260499]-specific supportive measures (e.g. steroids for pembroliz umab  -related  immune 
toxicities)  
• Drug -related toxicity, regardless of CTCAE grade, that results in an interruption of any 
component of study therapy during Cycle 1 for more than 21 consecutive days and cannot 
be controlled within 2 weeks from its onset 
• Any other Grade 2 or greater non- hematological toxicity that in the judgment of the  
investigator and Sponsor Investigator is dose limiting, with the exception of mild or moderate immune -mediated adverse reactions or symptomatic endocrinopathy 
attributable to  pembrolizumab 
• For Liver Function Tests 
- ALT or AST  ≥8x ULN  
- ALT or AST ≥5x ULN but <[ADDRESS_260500] persists for ≥[ADDRESS_260501]  ≥3x ULN if associated with the appearance or worsening of 
symptoms  of hepatitis or hypersensitivity such as fatigue, nausea, vomiti ng, right 
upper quadrant pain or tenderness, pyrexia, rash or eosinophilia. 
The following will NOT be considered a DLT for the purposes of this protocol: 
• Clinically insignificant laboratory values of any grade (i.e. asymptomatic amylase, lipase 
elevations) . 
 
Dose escalation will proceed within each cohort according to the following scheme.  Dose-
limiting toxicity (DLT) is defined above.   
The MTD is the highest dose tested in which ≤ 1 out of 6 patients has experienced a DLT. 
Products:  Pembrolizumab/Trametinib   UCDCC#259  
  v.Original (05/09/2017)  
 
UC Davis Comprehensi ve Cancer Center  
Confidential   Page 35 of 87 Table 15: Dose Escalation Decision Rule Summary  
Number of Patients with DLT  
at a Given Dose Level  Escalation Decision Rule  
0 out of 3  Enter 3 patients at the next dose level.  
≥2 Dose escalation will be stopped.  This dose level will be 
declared the maxim um administered dose (highest dose 
administered).  Three (3) additional patients will be 
entered at the next lowest dose level if only [ADDRESS_260502] 3 more patients at this dose level.  
• If 0 of these 3 patients experience DLT, proceed to the 
next dose level.  
• If 1 or more of this group suffer DLT, then dose escalation is stopped, and this dose is declared the 
maximally administered dose.  Three (3) additional 
patients will be entered at the next lowest dose level if only 3 patients were treated previously at that dose.  
≤[ADDRESS_260503] dose level below the 
maximum  administered dose (unless ≤[ADDRESS_260504] DLT’s at Dose Level 2 – in 
which case this is also the MTD).  This is the maximum tolerated dose (MTD), and generally 
the recommended phase 2 dose (RP2D) . At least [ADDRESS_260505] be entered at the RP2D . 
 
If ≤[ADDRESS_260506] DLT, this will be declared the maximum 
administered dose and the presumptive RP2D.  The RP2D may be less than the MTD or the 
maximum administered dose, depending on toxicities in later cycles and the extent of toxicities 
not qualifying as DLT. 
5.5 Concomitant Medications/Vaccinations (allowed & prohibited)  
Medications or vaccinations specifically prohibited in the exclusion criteria are not allowed 
during the ongoing trial.  If there is a clinical indication for one of these or other medications or vaccinations specifically prohibited during the trial, discontinuation from tri al therapy or 
vaccination may be required.  The investigator should discuss any questions regarding this with the [COMPANY_006] C linical team.  The final decision on any supportive therapy or vaccination rests with 
the investigator and/or the subject's primary phy sician.  
5.5.[ADDRESS_260507]’s welfare may be administered at the discretion of the investigator in keepi[INVESTIGATOR_77981].  All concomitant  medication will be recorded in the subject’s medical record  
including all prescription, over-the-counter (OTC), herbal supplements, and IV medications and fluids.  If changes occur during the trial period, documentation of drug dosage, frequency, route, and date may also be included in the subject’s medical record . 
Products:  Pembrolizumab/Trametinib   UCDCC#259  
  v.Original (05/09/2017)  
 
UC Davis Comprehensi ve Cancer Center  
Confidential   Page [ADDRESS_260508] dose of trial treatment should be recorded for SAEs and 
ECIs as defined in Section 7.2. 
5.5.2 Prohibited Concomitant Medications  
Subjects are prohibited from receiving the following therapi[INVESTIGATOR_216685] t Phase of this trial: 
• Antineoplastic systemic chemotherapy or biological therapy  
• Immunotherapy not specified in this protocol 
• Chemotherapy not specified in this protocol 
• Investigational agents other than pembrolizumab 
• Radiation therapy
  
Note:  Radiation therapy to a symptomatic solitary lesion or to the brain may be allowed at the investigator’s discretion .   
• Live vaccines within [ADDRESS_260509] dose of trial treatment and while 
participating in the trial.   Examples of live vaccines include, but are not limited to, the 
following: measles, mumps, rubella, varicella/zoster , yellow fever, rabies, BCG, and 
typhoid vaccine.  
• Systemic glucocorticoids for any purpose other than to modulate symptoms from an event of clinical interest of suspected immunologic etiology.  The use of physiologic 
doses of corticosteroids may be approved after consultation with the Investigator. 
Subjects who, in the assessment by [CONTACT_093], require the use of any of the aforementioned treatments for clinical management should be removed from the trial.  Subjects may receive other medications that the investigator deems to be medically necessary.  
The Exclusion Criteria describes other medications which are prohibited in this trial.  
There are no prohibited therapi[INVESTIGATOR_3927]- Treatment Follow -up Phase. 
5.6 Rescue Medications & Supportive Care  
5.6.1 Supportive Care Guidelines  
5.6.2 Pembrolizumab  
Subjects should receive appropriate supportive care measures as deemed necessary by [CONTACT_12707].  Suggested supportive care measures for the management of adverse events 
Products:  Pembrolizumab/Trametinib   UCDCC#259  
  v.Original (05/09/2017)  
 
UC Davis Comprehensi ve Cancer Center  
Confidential   Page 37 of 87 with potential immunologic etiology are outlined below. Where appropriate, t hese guidelines 
include the use of oral or intravenous treatment with corticosteroids as well as additional anti-
inflammatory agents if symptoms do not improve with administration of corticosteroids.   Note 
that several courses of steroid tapering may be necessary as symptoms may worsen when the steroid dose is decreased. For each disorder, attempts should be made to rule out other causes such as metastatic disease or bacterial or viral infection, which might require additional supportive care. The treatment guidelines are intended to be applied when the investigator  
determines the events to be related to pembrolizumab.  
Note: if after the evaluation the event is determined not to be related, the investigator  does not 
need to follow the treatment guidance (as outlined below). Refer to Section 5.2.1 for dose 
modification.  It may be necessary to perform conditional procedures such as bronchoscopy, endoscopy, or skin 
photography as part of evaluation of the event.  
• Pneumonitis :  
o For Grade 2 events , treat with systemic corticosteroids. When symptoms 
improve to Grade 1 or less, steroid taper should be started and continued over no less than 4 weeks.  
o For Grade 3 -4 events , immediately treat with intravenous steroids.  Administer 
additional anti- inflammato ry measures, as needed.  
o Add prophylactic antibiotics for opportunistic infections in the case of prolonged steroid administration
. 
• Diarrhea/Colitis :  
 Subject s should be carefully monitored for signs and symptoms of enterocolitis (such as 
diarrhea, abdominal pain, blood or mucus in stool, with or without fever) and of bowel perforation (such as peritoneal signs and ileus).   
o All subjects who experience diarrhea/colitis  should be advised to drink liberal 
quantities of clear fluids.  If sufficient oral fluid intake is not feasible, fluid and electrolytes should be substituted via IV infusion.  For Grade 2 or higher diarrhea, consider GI consultation and endoscopy to confirm or rule out colitis.  
o For Grade 2 colitis , administer oral corticosteroids.  
o For Grade 3 or 4 colitis , treat with intravenous steroids followed by [CONTACT_180731].   
o When symptoms improve to Grade 1 or less, steroid taper should be started and continued over no less than 4 weeks. 
Products:  Pembrolizumab/Trametinib   UCDCC#259  
  v.Original (05/09/2017)  
 
UC Davis Comprehensi ve Cancer Center  
Confidential   Page 38 of 87 • Type 1 diabetes mellitus (if new onset, including diabetic ketoacidosis [DKA]) 
or Grade ≥3 Hyperglycemia, if associated with ketosis (ketonuria) or metabolic 
acidosis (DKA)  
o For T1DM  or Grade 3 -4 Hyperglycemia  
 Insulin replacement therapy is recommended for Type I diabetes mellitus 
and for Grade 3- 4 hyperglycemia associated with metabolic acidosis or 
ketonuria.  
 Evaluate patients with serum glucose and a metabolic panel, urine ketones, glycosylated hemoglobin, and C-peptide.  
• Hypophysitis : 
o For Grade 2  events, treat with corticosteroids. When symptoms improve to Grade 
1 or less, steroid taper should be started and continued over no less than 4 weeks. Replacement of appropriate hormones may be required as the steroi d dose is 
tapered.  
o For Grade 3 -4 events, treat with an initial dose of IV corticosteroids followed by 
[CONTACT_78019]. When symptoms improve to Grade 1 or less, steroid taper should be started and continued over no less than 4 weeks. Replacement of appropriate hormones may be required as the steroid dose is tapered. 
• Hyperthyroidism or Hypothyroidism :  
 Thyroid disorders can occur at any time during treatment. Monitor patients for changes in thyroid function (at the start of treatment, periodically duri ng treatment, and as indicated 
based on clinical evaluation) and for clinical signs and symptoms of thyroid disorders. 
o Grade 2  hyperthyroidism events (and Grade 2-4 hypothyroidism): 
 In hyperthyroidism, non- selective beta -blockers (e.g. propranolol) are 
suggested as initial therapy.  
 In hypothyroidism, thyroid hormone replacement therapy, with levothyroxine or liothyroinine, is indicated per standard of care. 
o Grade 3 -4 hyperthyroidism  
 Treat with an initial dose of IV corticosteroid followed by [CONTACT_216739]. When symptoms improve to Grade 1 or less, steroid taper 
should be started and continued over no less than 4 weeks. Replacement of appropriate hormones may be required as the steroid dose is tapered.  
Products:  Pembrolizumab/Trametinib   UCDCC#259  
  v.Original (05/09/2017)  
 
UC Davis Comprehensi ve Cancer Center  
Confidential   Page 39 of 87 • Hepatic : 
o For Grade 2  events, monitor liver function tests more frequently until returned to 
baseline values (consider weekly).  
 Treat with IV or oral corticosteroids  
o For Grade 3 -4 events, treat with intravenous corticosteroids for 24 to 48 hours.  
o When symptoms improve to Grade 1 or less, a steroid taper should be started and 
continued over no less than 4 weeks. 
• Renal Failure or Nephritis : 
o For Grade 2  events, treat with corticosteroids. 
o For Grade 3 -4 events, t reat with systemic corticosteroids . 
o When symptoms improve to Grade 1 or less, steroid taper should be started and continued over no less than 4 weeks.   
• Management of Infusion Reactions : Signs and symptoms usually develop during or 
shortly after drug infusion and generally  resolve completely within [ADDRESS_260510] s who experience an infusion reaction 
associated with administration of pembrolizumab ( MK-3475).  May follow institutional 
guidelines.   
Products:  Pembrolizumab/Trametinib   UCDCC#259  
  v.Original (05/09/2017)  
 
UC Davis Comprehensi ve Cancer Center  
Confidential   Page 40 of 87 Table 16. Infusion Reaction Treatment Guidelines 
NCI CTCAE Grade  Treatment  Premedication at 
subsequent dosing  
Grade 1  
Mild reaction; infusion 
interruption not indicated; 
intervention not indicated  Increase monitoring of vital signs as medically indicated until the 
subject is deemed medically stable in the o pi[INVESTIGATOR_871] , 
or per institutional policies . None  
Grade 2  
Requires infusion interruption but responds promptly to symptomatic treatment (e.g., 
antihistamines, NSAIDS, 
narcotics, IV fluids); prophylactic medications indicated for < =24 hrs  Stop Infusion and monitor symptoms . 
Additional appropriate medical therapy may include but is not limited to:  
IV fluids  
Antihistamines  
NSAIDS  
Acetaminophen  
Narcotics  
Increase monitoring of vital signs as medically indicated until the 
subject is deemed medi cally stable in the opi[INVESTIGATOR_871].  
If symptoms resolve within one hour of stoppi[INVESTIGATOR_13056], the 
infusion may be restarted at 50% of the original infusion rate (e.g., from 100 mL/hr to 50 mL/hr).  Otherwise dosing will be held until 
symp toms resolve and the subject should be premedicated for the 
next scheduled dose.  
Subjects who develop Grade [ADDRESS_260511] may be 
premedicated 1.5h (±30 minutes) prior to infusion of pembrolizumab 
(MK-3475) with:  
Diphenhydramine 50 
mg po (or equivalent dose of 
antihistamine). 
Acetaminophen 500-
1000 mg po (or equivalent dose of 
antipyretic).  
Grades 3 or 4  
Grade 3:  
Prolonged (i.e., not 
rapi[INVESTIGATOR_86025]/or brief interruption of 
infusion); recurrence of 
symptoms following initial improvement; hospi[INVESTIGATOR_14138] 
(e.g., renal impairment, 
pulmonary infiltrates)  
Grade 4:  
Life-threateni ng; pressor 
or ventilatory support indicated  Stop Infusion . 
Additional appropriate medical therapy may include but is not 
limited to:  
IV fluids  
Antihistamines  
NSAIDS  
Acetaminophen  
Narcotics  
Oxygen  
Pressors  
Corticosteroids  
Epi[INVESTIGATOR_216686].  
Hospi[INVESTIGATOR_13021].  
Subject is permanently discontinued from further trial 
treatment administration . No subsequent 
dosing  
 Appropriate resuscitation equipment should be available in the room and a physician readily available during the period 
of drug administration.  
 
  
Products:  Pembrolizumab/Trametinib   UCDCC#259  
  v.Original (05/09/2017)  
 
UC Davis Comprehensi ve Cancer Center  
Confidential   Page 41 of 87 5.6.3 Supportive Care for Trametinib  
Rash is a frequent AE observed in subjects receiving trametinib (see the Investigator Brochures 
for more information). Recommendations for supportive care and guidelines for dose 
modifications for rash are based on experience with other MEK inhibitors [9] and EGF R 
inhibitors [10] and are provided in the table below and in the dose modification section for rash. 
Additional supportive care guidelines for trametinib and pembrolizumab are included in the dose modification guidelines in section 5.2. 
Table 17. Guidelines for Supportive Care of Rash from Trametinib  
Type of Care  Action  
 
Prevention  
/Prophylaxisa 
 • Avoid unnecessary exposure to sunlight  
• Apply broad- spectrum sunscreen (containing titanium dioxide or zinc oxide) with a 
skin protection factor (SPF) ≥[ADDRESS_260512] twice daily.  
• Use thick, alcohol -free emollient cream (e.g., glycerine and cetomacrogol cream) 
on dr y areas of the body at least twice daily.  
• Topi[INVESTIGATOR_216687] [ADDRESS_260513], and upper back.   
Use mild -strength topi[INVESTIGATOR_216688]  (hydrocortisone 1% cream) o r topi[INVESTIGATOR_11978] 
(e.g., clindamycin) or oral antibiotics (e.g., doxycycline 100 mg BID, minocycline 100 mg BID)  
 
Symptomatic Care
b  • Pruritic lesions: cool compresses and oral antihistamine therapi[INVESTIGATOR_014]  
• Fissuring lesions: Monsel’s  solution, silver nitrate, or zinc oxide cream  
• Desquamation: thick emollients and mild soap  
• Paronychia: antiseptic bath, local potent corticosteroids in addition to oral 
antibiotics; if no improvement, consult dermatologist or surgeon  
• Infected lesions: appropriate bacterial/fungal culture -driven systemic or topi[INVESTIGATOR_216689]:  BID = twice daily; SPF = sun protection factor  
a  Rash prophylaxis is recommended for the first 6 weeks of study treatment  
b  Subjects who develop rash/skin toxicities should be seen by a qualified physician and should receive evaluation for 
symptomatic/supportive care management  
 
5.7 Diet/Activity/Other Considerations  
5.7.[ADDRESS_260514] adverse effects on a fetus in utero.  Furthermore, it is not known if 
pembrolizumab has transient adverse effects on the composition of sperm.   
Products:  Pembrolizumab/Trametinib   UCDCC#259  
  v.Original (05/09/2017)  
 
UC Davis Comprehensi ve Cancer Center  
Confidential   Page [ADDRESS_260515] 
azoospermia (whether due to having had a vasectomy or due to an underlying medical 
condition).   
Female subjects will be considered of non-reproductive potential i f they are either:  
(1) postmenopausal (defined as at least 12 months with no menses without an alternative medical 
cause; in women < 45 years of age a high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post- meno pausal state in women not using 
hormonal contraception or hormonal replacement therapy. In the absence of 12 months of 
amenorrhea, a single FSH measurement is insufficient.);  
OR  
(2) have had a hysterectomy and/or bilateral oophorectomy, bilateral salpi[INVESTIGATOR_139595]/occlusion, at least 6 weeks prior to screening;  
OR  
(3) has a congenital or acquired condition that prevents childbearing. 
Female and male subjects of reproductive potential must agree to avoid becoming pregnant or 
impregnating a partner, respectively, while receiving study drug and for [ADDRESS_260516] 
dose of study drug by [CONTACT_139649]:   
(1) practice abstinence
† from h eterosexual activity;  
OR  
(2) use (or have their partner use) acceptable contraception during heterosexual activity.   Acceptable methods of contraception are
‡: 
Single method (one of the following is acceptable): 
• intrauterine device (IUD)  
• vasectomy of a female subject’s male partner  
• contraceptive rod implanted into the skin 
 Combination method (requires use of two of the following): 
• diaphragm with spermicide (cannot be used in conjunction with cervical cap/spermicide) 
• cervical cap with spermicide (nullipa rous women only)   
• contraceptive sponge (nulliparous women only)  
• male condom or female condom (cannot be used together) 
• hormonal contraceptive: oral contraceptive pi[INVESTIGATOR_4382] (estrogen/progestin pi[INVESTIGATOR_64870]-only 
pi[INVESTIGATOR_4382]), contraceptive skin patch, vaginal contraceptive ring, or subcutaneous contraceptive 
injection  
 †Abstinence (relative to heterosexual activity) can be used as the sole method of contraception if 
it is consistently employed as the subject’s preferred and usual lifestyle and if considered acceptable by [CONTACT_176742]/IRBs.  Periodic abstinence (e.g., calendar, ovulation, sympto-thermal, post-ovulation methods, etc.) and withdrawal are not acceptable 
methods of contraception.  
Products:  Pembrolizumab/Trametinib   UCDCC#259  
  v.Original (05/09/2017)  
 
UC Davis Comprehensi ve Cancer Center  
Confidential   Page 43 of 87 ‡If a contraceptive method listed above is restrict ed by [CONTACT_427]/guidelines, then it does 
not qualify as an acceptable method of contraception for subjects participating at sites in this 
country/region. 
Subjects should be informed that taking the study medication may involve unknown risks to the 
fetus (unborn baby) if pregnancy were to occur during the study.  In order to participate in the study subjects of childbearing potential must adhere to the contraception requirement (described above) from the day of study medication initiation (or 14 days prior to the initiation of study medication for oral contraception) throughout the study period up to [ADDRESS_260517] inadvertently becomes pregnant while on treatment with pembrolizumab and/or 
trametinib, the subject will immediately be removed from the study.  The  site will contact [CONTACT_216740]’s status until the pregnancy has been completed or terminated.  The outcome of the pregnancy will be reported to the Sponsor Investigator and to [COMPANY_006] and to [COMPANY_001] without delay and within 24 hours to the Sponsor Investigator and within 2 working days to [COMPANY_006] and [COMPANY_001] if the outcome is a serious adverse experience (e.g., death, abortion, congenital anomaly, or other disabling or life- threatening 
complication to the mother or newborn).   
The study investigator will make every effort to obtain permission to follow the outcome of the 
pregnancy and report the condition of the fetus or newborn to the Sponsor Investigator , [COMPANY_006] 
and [COMPANY_001] .   If a male subject impregnates his fema le partner the study personnel at the site 
must be informed immediately and the pregnancy reported to the Sponsor Investigator and to [COMPANY_006]  and to [COMPANY_001] and followed as described above and in Section 7.2.2. 
5.7.[ADDRESS_260518] Withdrawal/Dis continuation Criteria  
Subjects may withdraw consent at any time for any reason or be dropped from the trial at the discretion of the investigator should any untoward effect occur.  In addition, a subject may be withdrawn by [CONTACT_216741], the trial plan is violated, or for administrative and/or other safety reasons.  Specific details regarding discontinuation or withdrawal are provided in Section 7.1.3 – Other Procedures.  
 
 
Products:  Pembrolizumab/Trametinib   UCDCC#259  
  v.Original (05/09/2017)  
 
UC Davis Comprehensi ve Cancer Center  
Confidential   Page [ADDRESS_260519] be discontinued from the trial for any of the following reasons: 
• The subject or legal representative (such as a parent or legal guardian) withdraws 
consent. 
• Confirmed radiographic disease progression  
Note: For unconfirmed radiographic disease progression, please see Section 5.2.2  Note: A subject may be granted an exception to continue on treatment with confirmed radiographic progression if clinically stable or clinically improved.  
• Unacceptable adverse experiences as described in Section [IP_ADDRESS] 
• Intercurrent illness that prevents further administration of treatment  
• Investigator’s decision to withdraw the subject 
• The subject has a confirmed positive serum pregnancy test 
• Noncompliance with trial treatment or procedure requirements  
• The subject is lost to follow-up 
• Completed 24 months of uninterrupted treatment with pembrolizumab. Trametinib may 
be continued longer.  Note: [ADDRESS_260520] dose.  
• Administrative reasons  
The End of Treatment and Follow-up visit procedures are listed in Section 6 (Study Calendar ) 
and Section 7.1.4 (Visit Requirements).  After the end of treatment, each subject will be followed for 30 days for adverse event monitoring (serious adverse events will be collected for 90 days after the end of treatment as described in Section [IP_ADDRESS]).  Subjects who discontinue for reasons other than progressive disease will have post- treatment follow -up for disease status until disease 
progression, initiating a non- study cancer treatment, withdraw ing consent or becoming lost to 
follow-up.  After documented disease progression each subject will be followed by [CONTACT_80075], withdrawal of consent, or the end of the study, whichever occurs first. 
 
Products:  Pembrolizumab/Trametinib   UCDCC#259  
  v.Original (05/09/2017)  
 
UC Davis Comprehensi ve Cancer Center  
Confidential   Page [ADDRESS_260521] Replacement Strategy  
N/A 
5.10 Clinical Criteria for Early Trial Termination  
Early trial termination will be the result of the criteria specified below:  
1. Quality or quantity of data recording is inaccurate or incomplete  
2. Poor adherence to protocol and regulatory requirements 
3. Incidence or severity of adverse drug reaction in this or other studies indicates a potential 
health hazard to subjects 
4. Plans to modify or discontinue the development of the study drug 
In the event of [COMPANY_006] ’s or [COMPANY_001]’ decision to no longer supply study drugs , ample notification 
will be provided so that appropriate adjustments to subject treatment can be made. 
 
Pembrolizumab /Trametinib  UCDCC#259  
v.Original (05/09/2017)  
  
 
  
 
 6.0 STUDY CALENDAR  
Time Period:  Screening Phase  Treatment Cycle1 End of Treatment  Post-Treatment  
Treatment Cycle/Title : Main Study 
Screening (Visit 1)  [ADDRESS_260522] 
Discontinuation14 Follow -
up15 Survival 
Follow -
up16 5 6 7 8 
Scheduling Window (Days):  -28 to -1  ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 At time of 
Discontinuation  
Administrative Procedures               
Informed Consent  X            X 
Inclusion/Exclusion Criteria  X             
Demographics and Medical History  X             
Prior and Concomitant Medication Review  X             
Trial Treatment Administration8  X X X X X X X X     
Survival Status   X ------------------ Ongoing ---------- ------ X X X X 
Clinical Procedures/Assessments1,2        
Review Adverse Events   X ----------- ------ Ongoing -------- ---------  X X   
Full Physical Examination  X             
Directed Physical Examination   X1 X X X X X X X X X   
Vital Signs , Weight  and Height  
(height only at screening).  X X1 X X X X X X X X X   
ECOG Performance Status  X X X X X X X X X X X   
Ophthalmology Exam11 X As clinically indicated     
ECG13 X X X X     X     
ECHO/MUGA12 X    X    X     
Laboratory Procedures/Assessments5,[ADDRESS_260523] – Urine or Serum β-HCG3 X             
PT/INR and aPTT4 X             
CBC with Differential  X  X X X X X X X X X   
Comprehensive Serum Chemistry Panel  X  X X X X X X X X X   
Urinalysis  X             
T3, FT4 and TSH  X  X  X  X  X X X   
Efficacy Measurements        
Tumor Imaging7 X Every 9 weeks while on treatment  X X X  
Tumor Biopsies/Archival Tissue Collection/Correlative Studies Blood      
Archival or Newly Obtained Tissue Collection9 X X        X    
Correlative Studies Blood Collection10 X X X X X X X X X X    
Pembrolizumab /Trametinib  UCDCC#259  
v.Original (05/09/2017)  
  
 
  
 
 1.  In general, assessments/procedures are to be performed on Day [ADDRESS_260524] dose of trial treatment for each cycle  unless otherwise specified. Treatment cycles are 3 weeks 
(21-days); however the pembrolizumab (MK -3475) treatment cycle interval may be increased due to toxicity according to the dose modification guidelines provided. If tr eatment 
cycles are increased all procedures except imaging will be completed according to the Cycle number and not weeks on treatment, imaging will be performed every 9 weeks (± 3 days) 
from the first dose of trial treatment regardless of any treatment delays. Weekly visits will also occur for the first cycle when starting trametinib (when trametinib is added (Cohort A 
C1D1, Cohort B C2D1).  The first cycle where both drugs are given requires weekly clinic visits for review of adverse events,  vital signs, ECOG performance status, directed physical 
exam and CBC and CMP.  
2. In general, the window for each visit is ± [ADDRESS_260525], performed by [CONTACT_79428], will be required. Pregnancy tests (serum and/or urine tests) should be repeated if required 
by [CONTACT_13144].  
4. Coagulation factors (PT/INR and aPTT) should be monitored closely throughout the trial for any subject receiving anticoagulant therapy.  
5. Laboratory tests for screening are to be performed within [ADDRESS_260526] of specific laboratory procedures/assessments to be 
performed in this study.  
6. After Cycle 1, lab samples can be collected up to [ADDRESS_260527] dose of trial treatment.  On-study imaging will be performed every 9 weeks (63 ±7 
days) after the first dose of trial treatment or more frequently if clinically indicated. The timing for imaging studies should follow calendar days and should not be adjusted for delays in cycle starts  or extension of pembrolizumab  /trametinib cycle frequencies. The same imaging technique should be used in a subject throughout the trial. CT including the chest, 
abdomen and pelvis or PET -CT is required for the baseline assessment.   Patients who discontinue for reasons other than progression will be followed by [CONTACT_216742]  9 weeks . 
8. Pembrolizumab (MK -3475) can be administered for up to 2 years. For the dose escalation and expansion Cohort (Arm) A (concurrent trametinib and pembrolizumab (MK -3475) both 
drugs will be administered as outlined in this protocol starting with cycle #1. For cohort B. trametinib will be initiated wi th cycle #1 and pembrolizumab (MK -3475) will commence in 
combination with trametinib starting with cycle #2, for Cohort C pembroliz umab (MK -3475) will be given for cycle 1 with concurrent trametinib added on C2D1.  
9. Tumor biopsy for immune and molecular biomarker analysis will be performed prior to Cycle 1 of treatment either on archival tissue or fresh biopsy (within 6 months – no intervening 
treatment). Repeat biopsy will be performed on cycle [ADDRESS_260528] dose of trametinib for Arm A) and an optional end of study biopsy (within 28 days after 
progression).  
10.Correlative blood draws for immune correlates will be performed prior to cycle 1 ( - 3 days), prior to cycle 4 (-3 days), prior to cycle 7 (-3 days) and at discontinuation visit  (± 5 days). 
Correlative blood draws for plasma DNA/RNA will be performed at baseline (cycle 1, day 1 prior to dosing or prior during screening), prior to each cycle  of treatment ( prior to 
concurrent administration of trametinib and pembrolizumab ), and at progression (± 5 days).  
11. Ophthalmology Exam: Indirect fundoscopic examination, visual acuity (corrected), visual field examination, tonometry, and direct fundoscopy within 6 weeks prior to registration.  
12. ECHO/MUGA will be performed every [ADDRESS_260529].15. Subjects who discontinue trial treatment for a reason other than disease progression will move into the Follow -Up p hase and should be assessed every 9 
weeks (63 ±7 days) by [CONTACT_110531] .  
16. Once a patient has progression, they will be followed every 12 weeks until death or withdraw from follow -up. 
 
Products:  P embrolizumab /Trametinib  UCDCC#259  
  v.Original  (05/09/2017)  
Page 48 of 87 7.0 TRIAL PROCEDURES  
7.1 Trial Procedures  
The Study Calendar  - Section 6.0 summarizes the trial procedures to be performed at each visit.  
Individual trial procedures are described in detail below.  It may be necessary to perform these 
procedures at unscheduled time points if deemed clinically necessary by [CONTACT_20603].  
Furthermore, additional evaluations/testing may be deemed necessary by [CONTACT_216743]/ or [COMPANY_006] /[COMPANY_001]  for reasons related to subject safety. In some cases, such 
evaluation/testing may be potentially sensitive in nature (e.g., HIV,  Hepatitis C, etc.), and thus 
local regulations may require that additional informed consent be obtained from the subject.  In these cases, such evaluations/testing will be performed in accordance with those regulations.  
7.1.1 Administrative Procedures  
[IP_ADDRESS] Informed Consent  
The Investigator must obtain documented consent from each potential subject prior to participating in a clinical trial. 
[IP_ADDRESS].[ADDRESS_260530]’s dated signature [INVESTIGATOR_4388] [CONTACT_423]’s legally acceptable repr esentative’s dated signature [INVESTIGATOR_2394] a consent form along with the dated signature [CONTACT_80110].  
A copy of the signed and dated consent form should be given to the subject before participation 
in the trial.  
The initial informed consent form, any subsequent revised written informed consent form and any written information provided to the subject must receive the IRB/ERC’s approval/favorable opi[INVESTIGATOR_19349].  The subject or his/her legally acceptable representative should be informed in a timely manner if new information becomes available that may be relevant to the subject’s willingness to continue participation in the trial.  The communication of this information will be provided and documented via a revised consent form or addendum to the original consent form that captures the subject’s dated signature [INVESTIGATOR_4388] [CONTACT_423]’s legally acceptable representative’s dated signature.  
Specifics about a trial and the trial population will be added to the consent form template at the protocol level.   
The informed consent will adhere to IRB/ERC requirements, applicable laws and regulations and 
Sponsor Investigator requirements.  
Products:  P embrolizumab /Trametinib  UCDCC#259  
  v.Original  (05/09/2017)  
Page 49 of 87 [IP_ADDRESS] Inclusion/Exclusion Criteria  
All inclusion and exclusion criteria will be reviewed by [CONTACT_093] o r qualified designee to 
ensure that the subject qualifies for the trial.  
[IP_ADDRESS] Medical History  
A medical history will be obtained by [CONTACT_27404].  Medical history 
will include all active conditions, and any condition diagnosed within the prior [ADDRESS_260531] has enrolled in this study will be recorded separately and not listed as medical history.   
[IP_ADDRESS] Prior and Concomitant Medications Review  
[IP_ADDRESS].[ADDRESS_260532] has enrolled in this study 
will be recorded separately and not listed as a prior medication.  
[IP_ADDRESS].[ADDRESS_260533] during 
the trial.  All medications related to reportable SAEs and ECIs should be recorded as defined in Section 7.2. 
[IP_ADDRESS] Disease Details and Treatments  
[IP_ADDRESS].1 Disease Details  
The investigator or qualified designee will obtain prior and current details regarding disease 
status.   
[IP_ADDRESS].2 Prior Treatment Details  
The investigator or qualified designee will review all prior cancer treatments including systemic treatments, radiation and surgeries. 
[IP_ADDRESS].[ADDRESS_260534] will move 
into survival follow-up.  
Products:  P embrolizumab /Trametinib  UCDCC#259  
  v.Original  (05/09/2017)  
Page 50 of 87 7.1.2 Clinical Procedures/Assessments  
[IP_ADDRESS] Adverse Event (AE) Monitoring  
The investigator or qualified designee will assess each subject to evaluate for potential new or 
worsening AEs as specified in the Study Calendar and more frequently if clinically indicated.  Adverse experiences will be graded and recorded throughout the study and during the follow-up period according to NCI CTCAE Version 4.0 (see Section 1 1.6).  Toxicities will be characterized 
in terms regarding seriousness, causality, toxicity grading, and action taken with regard to trial treatment.  
Please refer to section 7.2 for detailed information regarding the assessment and recordi ng of 
AEs.   
[IP_ADDRESS] Full Physical Exam 
The investigator or qualified designee will perform a complete physical exam during the screening period.  Clinically significant abnormal findings should be recorded as medical history.  A full physical exam should be performed during screening,  
[IP_ADDRESS] Directed Physical Exam  
For cycles that do not require a full physical exam per the Study Calendar , the investigator or 
qualified designee will perform a directed physical exam as clinically indicated prior to trial 
treatment adminis tration.   
[IP_ADDRESS] Vital Signs  
The investigator or qualified designee will take vital signs at screening, prior to the administration of each dose of pembrolizumab treatment and at treatment discontinuation as specified in the Study Calendar (Section 6.0).  Vital signs should include temperature, pulse, 
respi[INVESTIGATOR_697], weight and blood pressure.  Height will be measured at screening only. 
[IP_ADDRESS] Eastern Cooperative Oncology Group (ECOG) Performance Scale 
The investigator or qualified designee will assess ECOG status (see Section 11.5) at screening, 
prior to the administration of each dose of trial treatment and discontinuation of trial treatment as 
specified in the Study Calendar.   
[IP_ADDRESS] Tumor Imaging and Asses sment of Disease   
This will be performed using RECIST 1.1 Criteria. 
  
Products:  P embrolizumab /Trametinib  UCDCC#259  
  v.Original  (05/09/2017)  
Page 51 of 87 [IP_ADDRESS] Tumor Tissue Collection and Correlative Studies Blood Sampling  
Molecular Studies Blood 
• Plasma DNA/RNA detection of KRAS and PD- L1 
• Prior to each cycle of treatment two tubes of blood (1 for RNA and 1 for DNA) will be 
collected for KRAS and PD -L1 DNA and RNA quantification. Tubes will be provided in 
a collection kit from Liquid Genomics. The assay will be performed by [CONTACT_216744], 
which has validated DNA and RNA assays for KRAS and PD- L1. Please see appendix 
for tube collection and shippi[INVESTIGATOR_3931].Immune studies blood - Peripheral blood 
will be collected prior to  cycle 1 ( -3 days), prior to cycle 4 (-3 days), prior to cycle 7 (-3 
days) , and at progression (± 5 days) for flow cytometry for immune cell subsets , DNA 
sequencing for T -cell repertoire , Luminex  Assay  for measurement  of cytokines (25 plea) 
in plasma  and supernatant after  activation  with CD3+  CD28 or PMA+Ionomycine will 
also be performed  in the HIMC  at UC Davis  at select time  points. These studies will be 
performed by [CONTACT_216745].  
From each patient, at the rel evant  time points indi cated in the study calendar, for the immune 
studies blood w ill be withdraw n dir ectly into two 10 mL lavender-topped (ED TA coated) 
tubes. Samples will be banked and s tored and assays r un at the Hum an Immune Monitori ng 
Core (D irector: Em anual  Maverakis laboratory at UC D avis). 
Cont act informa tion: Hum an Immune Monito ring Core (M averakis Laborator y) 
UC Davis  School of Medicine 
IRC Bldg.,  Room [ADDRESS_260535]. Sacramento  CA [ZIP_CODE] 
LAB:  [PHONE_4586] 
The HIMC l abora tory (D irector: Em anual  Maverakis, MD) is a r esear ch laboratory at UC 
Davis with both i mmunology experti se and the app ropri ate equipment to carry out t he proposed 
studi es. These studi es may include: Luminex Cytokine A ssays  to determine changes  in 
cytokine prof iles in res pons e to treatm ent and Flow Cytome try to detect changes  in immune 
cell s ubset s. 
The tubes should be cent rifuged  as soon as possible at approximately 800 x g for 10 minut es. 
Plasma should be transferred to a 15 mL conical tube and centrifuged  a second  time at 1000 – 
[ADDRESS_260536] asma in 500 ul a liquots 
into l abeled cryovials. For peripheral blood mononucl ear cell (PBMC ) pre paration, r eplace t he 
plasma removed w ith an equal amount of PBS (Ca and Mg fr ee) in the ori ginal lavender-top 
tubes, and then slowly l ayer it on top of the 15ml of Fi coll in a 50ml coni cal tube, followed 
by [CONTACT_216746] 800 x g for 20 minut es with the br eak off. The buffy coat, a whitis h layer 
of cells betw een the PBS and Ficol l layers above the r ed blood cell l ayer, should be collected 
and transferred into a new 50ml tube, w ashed  once w ith 50ml of PB S, re-suspended in an 
appropriate volume of freez ing m edium and then transferred into l abeled cryovials 
(107/ml/vial).  All cr yovials are t hen to be frozen  as rapi[INVESTIGATOR_216690], and stored in a - 70 
degree freezer  unti l batch analysis is f easible by [CONTACT_216747]. 
Products:  P embrolizumab /Trametinib  UCDCC#259  
  v.Original  (05/09/2017)  
Page 52 of 87 Molecular correlates tissue – whole exome sequencing, determination of mutational load and 
RNA sequencing will be performed by [CONTACT_216748]2C Team. A tube of 
blood will be collected for germline DNA comparison. Kits will be provided by [CONTACT_216749].  
Immune Studies Tissue  
Tumor biopsy at three time points with a biopsy prior to treatment, cycle  1, day 11 (+/ - 2 days) 
and within [ADDRESS_260537] -treatment  upon progression for immune correlates (optional), anti -
apoptotic proteins, p -ERK by [CONTACT_216750]. Next generation sequencing 
on baseline and post -progression biopsies will also be conducted by [CONTACT_216749] , 
conducted by [CONTACT_216751], the Broad institution ( NGS) , the Mack lab 
and Theranostics.  Studies performed at SU2C Core (Yale and Broad) are part of the the SU2C 
Lung Cancer Dream Team.  
Table 18.Tissue Summary  
 
 Order 
Prioritya Tissue Correlative 
Study  Baseline  C1D11- 13 Progression  Slidesc Cell 
Blocksb Institution  
1 IHC and QIF of  PD-L1 
and other Immune 
Proteins and Tumor 
Infiltrating Immune Cells  X X X 5 
minimum 
(10 ideal)  1 SU2C 
Immune Core  
2 Next Generation 
Sequencing (tissue + blood for germline DNA comparison)  X  X [ADDRESS_260538] 
Institute (SU2C Core)  
[ADDRESS_260539]  X X X 4 
minimum 
(10 ideal)  1 Mack Lab UC 
Davis, Theranostics  
5 YAP1/TAZ IHC  X - X 2 1 Bivona Lab, 
UCSF  
6 PDX  X - X Fresh 
Tissue  N/A Jackson 
Laboratory West  
a. Prioritization of tissue use and correlates in order from #1 to #5 for baseline biopsy. Biopsy on or around  C1D11 -D13  will 
be sent for Multiplex Immunofluorescence for p-MEK, DUSP6 and Immune IHC/QIF.  
b. Paraffin embedded cell block(s) may be substitu ted for slides.  
c. Unstained slides total cut from FFPE blocks at [ADDRESS_260540] contain a minimum of 20% tumor 
tissue.  Slides must be positively charged . 1 H&E slide should also be made for IHC and NGS.  
Please see the relevant corr elative study sections below for further details regarding proper collection, shippi[INVESTIGATOR_216691].  
Products:  P embrolizumab /Trametinib  UCDCC#259  
  v.Original  (05/09/2017)  
Page [ADDRESS_260541]  of  ca re  molecular  studies.  The 
remaini ng cores will be deliver ed to UC D avis Research Pathology, Pavilion Room 2P524 ( or 
corresponding local research lab at other trial sites ) and divi ded into [ADDRESS_260542]. Philip M ack or the UC Davis 
HIMC for stor age until sent for further t esting. 
If available, two  additional cores  should be i mmediately stored in 2ml of RNAlater 
solution (L ife Techno logies) (the tissue portion should be pr ocessed into pi [INVESTIGATOR_6928], each l ess 
than 0.5cm
3) for comprehens ive DNA/RNA sequencing at the Broad Institute . The Samples in 
RNAlater solution should be kept refrigerated until processed at  HIMC .  This should b e 
delivered to the Human I mmune M onito ring Core w ith the contact [CONTACT_20986]. If 
not enough cores are obtained DNA/RNA sequencing can be sent of the initial FFPE tissue  
Specimens  in RNA 
 Later should be shipped on cool packs  (Monday – Thursday only) to: 
Human Immune Monitoring Core (Maverakis Laboratory)  
Department  of Dermatology  
UC Davis School of Medicine IRC Bldg., Room [ADDRESS_260543].  Sacramento CA [ZIP_CODE] LAB: [PHONE_4586] 
Tissue from the second biopsy time point will be divided into the 2 research components with the procedures outlined above.  Component 1: at least 2 cores or enough tissue for 20 cut slides as specified for initial biopsy for FFPE for PD -L1 and additional IHC quantification by [CONTACT_216752] 2: remaining cores in RNA later solution then FFPE for DNA/RNA sequencing. ( If 
no cores were available for processing with RNA later in the initial biopsy, the repeat 
biopsy should all go through FFPE and not through an RNA later step ).  A research H&E 
slide will also be generated and reviewed by a research pathologist to confirm presence of t umor.  
Products:  P embrolizumab /Trametinib  UCDCC#259  
  v.Original  (05/09/2017)  
Page [ADDRESS_260544] 20 unstained 
slides or 2 cell block is available for analyses (Fine needle specimens or cell blocks from cytology specimens are not acceptable).  
Next Generation Sequencing (DNA and RNA (if enough tissue available) of a Customized SU2C Gene Panel will be performed at the Broad Institute as part of the SU2C Collaboration. This will be performed at baseline biopsy and post- progres sion biopsy. When requested the Broad Institute 
Samples lab will ship sample collection kits to research site.  A companion blood collection tube 
will also be provided and s hould be collected at baseline.  
Kits are specific for Material Type collected  
i. Label s – FFPE or Frozen Tumors 
ii. Labels – Blood or Buffy Coat Samples 
iii. Matrix Kits – DNA or RNA analytes  
1. Researcher fill kit & provides Sample Kit Metadata spreadsheet (example provided).  
2. Kits are shipped back to the Broad Institute Samples lab per instructions provided in the kits.  (See Attached Documents).  Specimens should be coded with a unique identifier (ie. 
patient number and biopsy number in sequence (ie. for patient 1, 001- 01 (baseline 
biopsy), 001- 02 (on-treatment biopsy), 001-03 (post progression biopsy). 
3. Sample Processing & Data Generation will proceed.   
(Turnaround Time is expected to be 5-6 weeks for Exome runs). RNA sequencing will be batched into runs of [ADDRESS_260545] so timeline will be more variable. 
  
Products:  P embrolizumab /Trametinib  UCDCC#259  
  v.Original  (05/09/2017)  
Page 55 of 87 Quantitative Immunofluorescence  
To demonstrate on target knockdown of MEK inhibition with trametinib, the Mack lab at UC 
Davis and Theranostics Health (Gaithersburg , MD) will bank tissue to perform multiplexed 
immunofluorescence and RPPA  for phospho- MEK , DUSP6  and associated pathway proteins on 
FFPE.  
The Mack laboratory at UC Davis has extensive experience in the multiplexed immunofluorescence assay including incorporation into NCI sponsored studies such as SWOG [ADDRESS_260546] study of the mTOR inhibitor everolim us as adjuvant therapy in Renal Cell 
Carcinoma and FGF/FGFR.  
Up to 10 unstained slides (minimum 4)  or [ADDRESS_260547] Sacramento, CA [ZIP_CODE] Phone: [PHONE_4587] Email: [EMAIL_415]
 
 
Patient -Derived Xenotransplants  
Collection of Specimen(s) 
Tissue for PDX should only be obtained at procedures performed on a Monday, Tuesday, 
Wednesday, or Thursday. The fresh specimen will be submitted directly and immediately to The Jackson Laboratory using the following procedures.  
a. The physician should obtain the maximum amount of tumor that is prudent at the time of 
biopsy or resection. Minimum sample size is a core measuring 8mm x  3mm. Please approximate 
these dimensions. 
b. The specimen should be collected following Institution Universal precautions SOP s for 
maintaining tissue integrity. Please remind all personnel that are involved in processing the 
sample that it will be implanted in profoundly immune deficient mice, which is why it is imperative that extra care be taken in sample collection to minimiz e the risk of transferring 
human bacteria to the mice.  
Handling of Specimens(s) 
The tumor sample should be placed in a 50 ml screw cap conical tube containing 40 ml RPMI 
buffer (without fetal calf serum); preferably within 30 minutes of tumor removal. Seal cap tightly with Parafilm. Sample should be refrigerated at 4°C until packed for shippi[INVESTIGATOR_216692]. 
 
Products:  P embrolizumab /Trametinib  UCDCC#259  
  v.Original  (05/09/2017)  
Page 56 of 87 Shippi[INVESTIGATOR_25476](s) 
The sealed conical tube containing RPMI & the tumor specimen must be wrapped in absorbent 
material (i.e. pap er towels) and placed in an airtight plastic bag (i.e. a ziplock bag). Pack the 
specimen into an insulated Styrofoam shipper with a refrigerated (4° C) cool pack (not frozen) to protect specimen from temperature fluctuations. All paperwork pertaining to the patient should be placed in a plastic bag, sealed tightly, and packed with the tissue shipment. Include the Jackson Laboratory Sample Submission Form. 
Ship by [CONTACT_216753]:  
The Jackson Laboratory 
In Vivo Services c/o Margaret Bundy o r James Keck  
[ADDRESS_260548] for sample coordination:  Margaret Bundy [PHONE_4588]. 
Creation of PDX is funded under a UC Davis – Jackson Laboratory Collaboration. 
 
Immune Studies Tissue  
   Immunohistochemistry and Quantitative Immunofluorescence  
      PD -L1 and Evaluation of TILS 
The PD -L1 immunohistochemistry will be performed in 3 -5 µm-thick histology preparations 
obtained from conventional biopsy formalin- fixed, paraffin -embedded (FFPE) tissue samples.  
The tumor PD-L1 protein will be tested using the FDA-approved Dako 22C3 assay using 
chromogenic immunohistochemistry in the Yale Pathology Labs or UC Davis under CLIA laboratory conditions. The scoring procedure will include the determination  of the percentage of 
positive cells in the tumor by a surgical pathologist using bright field microscopy. The score will be semi -quantitative and determined based on the percentage of positive cells. 
The level of major TIL subtypes, TIL activation/proliferation and expression of major immune inhibitory receptors will be evaluated using multiplexed quantitative immunofluorescence (QIF) 
performed in 3-5 µm-thick histo logy preparations obtained from formalin- fixed, paraffin -
embedded (FFPE) tissue samples, as previously reported [11] . We will perform three 
multiplexed QIF panels containing the following markers: Panel #1: DAPI/CD4/CD8/CD20; 
Panel #2: DAPI/CD3/Granzyme- B/Ki -67; and Panel #3: DAPI/CD3/PD- 1/TIM -3/LAG -3.  The 
Yale group has already performed validation of the antibodies and combined these markers into multiplexed QIF panels. Simultaneous measurements of the targets will be performed using multispectral imaging and the AQUA® method providing continuous fluorescence marker scores. Eventually , quantification of positive cells for each marker will also be performed using 
the Vectra multispectral imaging platform with the cell phenotypi[INVESTIGATOR_216693]® 
Products:  P embrolizumab /Trametinib  UCDCC#259  
  v.Original  (05/09/2017)  
Page 57 of 87 software; and reported as cell density (number of cells/area unit).See section 7.2.4 for processing 
and shippi[INVESTIGATOR_216694]-L1 and QIF samples. 
Immune correlates  will be performed  by [CONTACT_216754] -Oncology or 
the Human  Immune Monitoring  Core (HIMC) at  UC Davis  as outlined below. 
 
PD-L1 expression will be assayed  using [COMPANY_006]’s proprietary 22C3 antibody  that is FDA 
approved as a companion diagnostic for pembrolizumab for quantifying PD -L1 expression for 
MK-3475 trials in NSCLC and melanoma including  [12]. 
Biopsied tumor for PD -L1 Quantification 
PD-L1 expression  by [CONTACT_216755]-L1 expression  in response to treatment  will be conducted  by [CONTACT_216756] -Oncology using the FDA approved DAKO 22C3 
antibody and  by [CONTACT_216757]. 
If there is not enough tissue for entire DNA/ RNA sequencing panel at the Broad Institute 
biopsied tumor for Tumor Infiltrating Lymphocytes and Subsets and RT- PCR for Immune 
Markers  Real  time-PCR for immune markers  (if tissue  size permits)  including CD3, PD-1, 
GranzB,  Perforin,  IL-2, IFNg, Tim3, LAG3,  CTLA -4, Foxp3 will be performed  if adequate tissue  
is available.  
Processing Instructions  for Immunohistochemistry and Quantitative Immunofluorescence  
Immunohistochemistry and Quantitative Immunofluorescence: Staining for PD -L1, relevant 
immunoproteins and tumor infiltrating immune cells will be perf ormed by [CONTACT_216758]2C Immune 
Core at Yale University as outlined below.  Tissue samples will be collected from participants 
who have been properly consented and who have agreed to participate in the research study. 
Tumor tissues are optimally suitable for IHC/Q IF studies if fixed in 10% neutral buffered 
formalin (NBF) for [ADDRESS_260549] the tumor block and obtain one Hematoxylin & Eosin (H& E) stained slide for 
review by [CONTACT_216759].  For in situ analyses, there is no lower limit in the amount of tumor cell content.   
 a. Samples with few tumor cells (<100 -200 cells) may be insuffic ient for PD -L1 
immunostaining but should still be submitted  for the QIF studies of TILs and other 
stromal markers.  
 
2. If pathologist review is not possible or available at the site, the H&E slides or a digital 
version may be sent directly to Yale Pathology f or initial assessment.  
 
3. Obtain [ADDRESS_260550] each section in a positively -charged glass histology slide.  Tissues should be cut 
Products:  P embrolizumab /Trametinib  UCDCC#259  
  v.Original  (05/09/2017)  
Page [ADDRESS_260551] 5 freshly cut (<5 days) unstained serial section slides from each case, label each 
preparation using the SU2C coding system and place them in a conventional plastic histology slidebox.  Make sure slides are in a firm position to avoid damage during transportation and cover with paper towel prior to packing to prevent movement within the box.  If possible, also include the sectioning order on the label for each slide. 
 
a.  Whenever feasible, blocks should be processed in batches, and shipped together within 
a 5-day period after sectioning. 
 
5. Include H&E stained preparation together with the 5 unstained sections in the slidebox.  
This slide will be digitalized and become available for review within the SU2C group.  Specimens should be coded with a unique identifier (ie. ins titution, trial number, patient 
number and biopsy  number in sequence (ie. for UC Davis patient 1, UCD250-001-01 
(baseline biopsy), UCD250-001-02 (on-treatment biopsy), UCD250-001-03 (post progression biopsy).  
6. Seal the slidebox using Parafilm and/or a plastic envelope and wrap with bubble wrap 
prior to shippi[INVESTIGATOR_007].  Include detailed sender information (with email) and ship using overnight service to: 
 
Attention to: Nikita Mani ([EMAIL_4237]).   Backup contact [CONTACT_216760] ([EMAIL_4238])  
Address: BML112/BML113    Department of Pathology     Yale School of Medicine  
    [ADDRESS_260552]  [ZIP_CODE] Phone 1:  [PHONE_4589] Phone 2:  [PHONE_4590] 
 
A confirmation of sample reception will be sent via email to the sender within 72 hours.  
 
7.  Slides will be stained for IHC and the QIF panels within 5 working days from reception 
in the lab or stored in appropriately until use and batched to accommodate projects in single experimental runs (whenever possible). 
 8. Results of the analyzed markers  will be provided as continuous scores using fluorescence 
intensity scores and/or phenotype cell counts.  The turnaround time will depend on the amount of slides and project volume.   
 
  
Products:  P embrolizumab /Trametinib  UCDCC#259  
  v.Original  (05/09/2017)  
Page 59 of 87 YAP1/TAZ Immunohistochemistry  
We will collect pre - and post - treatmen t tissues  as available. Formalin -fixed, paraffin -embedded 
(FFPE) slides will be applied for immunohistochemistry (IHC) staining with YAP and TAZ 
antibody separately. YAP1 antibody will be purchased from Santa Cruz Biotechnology (sc-[ZIP_CODE]). And TAZ antibody will be purchased from Sigma (HPA007415). The nuclear and cytosol YAP/TAZ expression will be quantified and scored by [CONTACT_17685]- certificated pathologists. 
The scores of YAP/TAZ expression in pre- and post- treatment will be compared to explore up regulation of YAP/TAZ as a biomarker of resistance to trametinib + pembrolizumab  treatment.  
These studies will be funded by [CONTACT_216761]. 
Collection of Specimen(s) Completion of both assays requires a total of 2 unstained slides cut from FFPE blocks at 5 
microns thickness on positively charged (+) slides.  
Shippi[INVESTIGATOR_25476](s): Bivona Laboratory  
Room N216R, Genentech Hall 
[ADDRESS_260553], San Francisco, CA [ZIP_CODE] Laboratory Procedures/Assessments 
Details regarding specific laboratory procedures/assessments to be performed in this trial are provided below. Laboratory Safety Evaluations (Hematology, Chemistry and Urinalysis) 
Laboratory tests for hematology, chemistry, urinalysis, and others are s pecified below.  
 
Products:  P embrolizumab /Trametinib  UCDCC#259  
  v.Original  (05/09/2017)  
Page 60 of 87 Table 19. Laboratory Tests 
Hematology  Chemistry  Urinalysis  Other  
Hematocrit  Albumin  Blood  Serum β -human chorionic gonadotropin † 
Hemoglobin  Alkaline phosphatase  Glucose    (β-hCG) † 
Platelet count  Alanine aminotransferase (ALT)  Protein  PT (INR)  
WBC (total and differential)  Aspartate aminotransferase (AST)  Specific gravity  aPTT  
Red Blood Cell Count  Lactate dehydrogenase (LDH)  Microscopic exam (If abnormal)   Total thriiodothyronine (T3)  
Absolute Neutrophil Count  Carbon Dioxide ‡ results are noted  Free thyroxine  (T4) 
Absolute Lymphocyte Count  (CO 2 or biocarbonate)  Urine pregnancy test † Thyroid  stimulating hormone (TSH)  
 Uric Acid    
 Calcium    
 Chloride   Blood for correlative studies  
 Glucose     
 Phosphorus     
 Potassium      
 Sodium     
 Magnesium     
 Total Bilirubin     
 Direct Bilirubin (If total bilirubin is elevated 
above the upper limit of normal)    
 Total protein    
 Blood Urea Nitrogen    
† Perform on women of childbearing potential only. If urine pregnancy results cannot be confirmed as negative, a serum pregna ncy test will be required.   
‡ If considered standard of care in your  region.  
 
Products:  Pembrolizumab /Trametinib   UCDCC#259  
  v.Original  (05/09/2017)  
 
Page [ADDRESS_260554] be reviewed by [CONTACT_79436].  
7.1.3 Other Procedures  
[IP_ADDRESS] Withdrawal/Discontinuation 
When a subject discontinues/withdraws prior to trial comple tion, all applicable activities 
scheduled for the discontinuation visit should be performed at the time of discontinuation.  Any adverse events which are present at the time of discontinuation/withdrawal should be followed in accordance with the safety req uirements outlined in Section 7.2 - Assessing and Recording 
Adverse Events.  Subjects who a) attain a  CR or b) complete 24 months of treatment with 
pembrolizumab may discontinue treatment.  Trametinib may be continued after 24 months. After 
discontinuing treatment following assessment of CR, these subjects should return to the site for a Safety Follow -up Visit (described in Section [IP_ADDRESS]) and then proceed to the Follow-Up Period 
of the study (described in Section [IP_ADDRESS]).  
7.1.4 Visit Requirements  
Visit require ments are outlined in Section 6.0 - Study Calendar .   Specific procedure- related 
details are provided above in Section 7.1 - Trial Procedures.  
[IP_ADDRESS] Screening  
Screening should be completed within 28 days of the patient signing consent. 
[IP_ADDRESS] Treatment Period  
Please see study calendar for treatment perio d details.  
[IP_ADDRESS] Post-Treatment Visits  
Only safety follow up period required. [IP_ADDRESS]  Safety Follow- Up Visit  
The mandatory Safety Follow -Up Visit should be conducted approximately [ADDRESS_260555].  All AEs that occur prior to the Safety Follow -Up Visit should be recorded.  Subjects with 
an AE of Grade > [ADDRESS_260556].  SAEs that occur within 90 days of the end of treatment or before initiation of a new anti-c ancer  treatment should also be 
followed and recorded.   
Products:  Pembrolizumab /Trametinib   UCDCC#259  
  v.Original  (05/09/2017)  
 
Page 62 of 87 [IP_ADDRESS] Follow- up Visits  
Subjects who discontinue trial treatment for a reason other than disease progression will move 
into the Follow-Up Phase and should be assessed every 9 weeks ( 63 ± 7 days) by [CONTACT_165919].  After 1 year, the imaging time poin t will occur every 9 weeks 
(± 7 days).  Every effort should be made to collect information regarding disease status until the 
start of new anti-neoplastic therapy, disease progression, death, or end of the study.  Information 
regarding post-study anti-neopl astic treatment will be collected if new treatment is initiated.  
[IP_ADDRESS].[ADDRESS_260557] a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure.  Any worsening (i.e., any clinically significant adverse change in frequency 
and/or intensity) of a preexisting condition that is temporally associated with the use of the [COMPANY_006] ’s product, is also an adverse event. 
Changes resulting from normal growth and development that do not vary significantly in frequency or severity from expected levels are not to be considered adverse events.  Examples of this may include, but are not limited to, teething, typi[INVESTIGATOR_216695] a t a physiologically appropriate time.  
[COMPANY_006]  product includes any pharmaceutical product, biological product, device, diagnostic agent 
or protocol-specified procedure, whether investigational (including placebo or active comparator medication) or marketed, manufactured by, licensed by, provided by [CONTACT_216762]. 
Adverse events may occur during the course of the use of [COMPANY_006]  product in clinical trials, or as 
prescribed in clinical practice, from overdose (whether accidental or intentional), from abuse and 
from withdrawal.  
Progre ssion of the cancer under study is not considered an adverse event.  
All adverse events that occur after the consent form is signed but before treatment allocation/randomization must be reported by [CONTACT_216763]:  Pembrolizumab /Trametinib   UCDCC#259  
  v.Original  (05/09/2017)  
 
Page 63 of 87 excluded from the trial, or are the result of a protocol-specified intervention, including but not 
limited to washout or discontinuation of usual therapy, diet, placebo treatment or a procedure. 
From the time of treatment allocation/randomization through [ADDRESS_260558] be reported by [CONTACT_093]. Such events will be recorded 
at each examination on the Adverse Event case report forms/worksheets.  The reporting timeframe for adverse events meeting any serious cri teria is described in section [IP_ADDRESS]. The 
investigator will make every attempt to follow all subjects with non -serious adverse events for 
outcome. 
7.2.1 Definition of an Overdose for t his Protocol and Reporting of Overdose to the 
Sponsor Investigator and to [COMPANY_006]  
For purposes of this trial, an overdose of pembrolizumab will be defined as any dose of 1,000 mg 
or greater (≥5 times the indicated dose).  No specific information is available on the treatment of 
overdose of pembrolizumab . Appropriate supportive treatment should be provided if clinically 
indicated.  In the event of overdose, the subject should be observed closely for signs of toxicity.  
Appropriate supportive treatment should be provided if clinically indicated. 
If an adverse event(s)  is associated with (“results from”) the overdose of a [COMPANY_006]  product, the 
adverse event(s) is reported as a serious adverse event, even if no other seriousness criteria are 
met. 
If a dose of [COMPANY_006] ’s product meeting the protocol definition of overdose is taken without any 
associated clinical symptoms or abnormal laboratory results, the overdose is reported as a non-
serious Event of Clinical Interest (ECI), using the terminology “accidental or intentional overdose without adverse effect.” 
All reports of overdose with and without an adverse event must be reported within 24 hours to 
the Sponsor Investigator and within 2 working days hours to [COMPANY_006]  Global Safety . (Attn: 
Worldwide Product Safety; FAX [PHONE_1840]) 
7.2.[ADDRESS_260559] (spontaneously reported to them) that occurs during the trial.  
Pregna ncies and lactations that occur after the consent form is signed but before treatment 
allocation/randomization must be reported by [CONTACT_26364], or are the result of a protocol -specified intervention, including but not 
limited to washout or discontinuation of usual therapy, diet, placebo treatment or a procedure.   
Pregnancies and lactations that occur from the time of treatment allocation/randomization 
through [ADDRESS_260560] be followed to the completion/termination of the 
Products:  Pembrolizumab /Trametinib   UCDCC#259  
  v.Original  (05/09/2017)  
 
Page [ADDRESS_260561] be reported as serious events (Important Medical Events). If the pregnancy continues to term, the outcome (health of infant) must also be reported. 
Such events must be reported within 24 hours to the Sponsor Investigator and within 2 working 
days to [COMPANY_006] Global Safety.  (Attn: Worldwide Product Safety; FAX [PHONE_1840]) 
7.2.3 Immediate Reporting of Adverse Events  to the Sponsor Investigator and to [COMPANY_006]  
[IP_ADDRESS] Serious Adverse Events  
A serious adverse event is any adverse event occurring at any dose or during any use of [COMPANY_006] ’s 
product that: 
• Results in death; 
• Is life threatening;  
• Results in persistent or significant disability/incapacity;  
• Results in or prolongs an existing inpatient hospi[INVESTIGATOR_059]; 
• Is a congenital anomaly/birth defect;  
• Is an other important medical event  
• Note: In addition to the above criteria, adverse events meeting either of the below criteria, 
although not serious per ICH definition, are reportable to the [COMPANY_006] in the same 
timeframe as SAEs to meet certain local requirements. Therefore, these events are considered serious by [CONTACT_131892]. 
o Is a n ew cancer (that is not a condition of the study); 
o Is associated with an overdose. 
Refer to Table 20 for additional details regarding each of the above criteria.  
For the time period beginning when the consent form is signed until treatment allocation/randomization, any serious adverse event, or follow up to a serious adverse event, including death due to any cause other than progression of the cancer under study that occurs to any subject must be reported within [ADDRESS_260562] to be excluded from the trial, or is the result of a protocol-specified intervention, including but not limited to washout or discontinuation of usual therapy, diet, placebo treatment or a procedure. 
For the time period beginning at treatment allocation/randomization through [ADDRESS_260563] initiates new 
anticancer therapy, whichever is earlier, any serious adverse event, or follow up to a serious adverse event, including death due to any cause other than progression of the cancer under study 
Products:  Pembrolizumab /Trametinib   UCDCC#259  
  v.Original  (05/09/2017)  
 
Page [ADDRESS_260564] be reported immediately to the Sponsor Investigator and to [COMPANY_006] Global Safety . 
• All subjects with serious adverse events must be followed up for outcome. 
• SAE reports and any other relevant safety information are to be forwarded to the 
[COMPANY_006] Global Safety facsimile number:  +1 -[PHONE_833] 
• A copy of all 15 Day Reports and Annual Progress Reports is submitted as required by [CONTACT_8415], European Union (EU), Pharmaceutical and Medical Devices agency (PMDA) or 
other local regulators. Investigators will cross reference this submission according to 
local regulations to the [COMPANY_006] Investigational Compound Number (IND, CSA, etc.) at the 
time of submission.  Additionally investigators will submit a copy of these reports to [COMPANY_006] & Co., Inc. (Attn: Worldw ide Product Safety; FAX [PHONE_1840]) at the time of 
submission to FDA. 
[IP_ADDRESS] Events of Clinical Interest  
Selected non -serious and serious adverse events are also known as Events of Clinical Interest 
(ECI) and must be reported within 24 hours to the Sponsor Investigator and within 2 working 
days to [COMPANY_006] Global Safety.  (Attn: Worldwide Product Safety; FAX [PHONE_1840]). 
For the time period beginning when the consent form is signed until treatment allocation/randomization , any ECI, or follow up to an ECI, that occurs to any subject must be 
reported within [ADDRESS_260565] to be excluded from the trial, or is the result of a protocol- specified 
intervention, including but not limited to washout or discontinuation of usual therapy, diet, placebo treatment or a procedure.  
For the time period beginning at treatment allocation/randomization through [ADDRESS_260566] for this trial include: 1.  an overdose of [COMPANY_006]  product, as defined in Section 7.2.1 - Definition of an Overdose for 
This Protocol and Reporting of Overdose to the Sponsor Investigator , that is not associated with 
clinical symp toms or abnormal laboratory results.  
Products:  Pembrolizumab /Trametinib   UCDCC#259  
  v.Original  (05/09/2017)  
 
Page [ADDRESS_260567] of protocol-specified laboratory testing or unscheduled laboratory testing.*  
*Note:  These criteria are based upon available regulatory guidance documents. The purpose of 
the criteria is to specify a threshold of abnormal hepatic tests that may require an additional evaluation for an underlying etiology.  
[IP_ADDRESS] Protocol -Specific Exceptions to Serious Adverse Event Reporting  
Efficacy endpoints as outlined in this section will not be reported to [COMPANY_006] as described in Section 7.2.3.- Immediate Reporting of Adverse Events to the Sponsor Investigator and to 
[COMPANY_006], unless there is evidence suggesting a causal relationship between the drug and the event.  
Any such event will be submitted to the Sponsor Investigator within 24 hours and to [COMPANY_006] Global Safety within 2 working days either by [CONTACT_131008]. 
Specifically, the suspected/actual events covered in this exception include any event that i s 
disease progression of the cancer under study.  
The Sponsor Investigator will monitor unblinded aggregated efficacy endpoint events and safety 
data to ensure the safety of the subjects in the trial. Any suspected endpoint which upon review is not progression of the cancer under study will be forwarded to [COMPANY_006] Global Safety as a SAE within 2 working days of determination that the event is not progression of the cancer under study. 
Hospi[INVESTIGATOR_77989] (e.g., transportation issues, etc.) w ill not be considered a 
SAE.  
Reporting Adverse Events to [COMPANY_001] 
To ensure patient safety, every SAE, regardless of suspected causality, occurring after the patient 
has provided the main informed consent and until at least [ADDRESS_260568] be reported as follow-up to the original epi[INVESTIGATOR_5319] 24 hours of the investigator receiving the follow-up information. An SAE occurring at a different time interval or otherwise considered completely unrelated to a previously reported one should be reported separately as a new event. 
Information about all SAEs is collected and recorded on the Serious Adverse Event Report 
Form; all applicable sections of the form must be completed in order to provide a clinically thorough report. The investigator must assess and record the relationship of each SAE to each specific study treatment (if there is more than one study treatment), complete the SAE Report 
Products:  Pembrolizumab /Trametinib   UCDCC#259  
  v.Original  (05/09/2017)  
 
Page 67 of 87 Form in English, and send the completed, signed form by [CONTACT_87109] 24 hours to the oncology 
[COMPANY_001] Drug Safety and Epi[INVESTIGATOR_623] (DS&E) department - Fax: ([PHONE_002]). The original copy of the SAE Report Form and the fax confirmation sheet must be kept with the case report form documentation at the study site. 
Follow-up information is sent to the same contact(s) to whom the original SAE Report Form was 
sent, using a new SAE Report Form st ating that this  is a follow -up to the previously reported 
SAE and giving the date of the original report. Each re-occurrence, complication, or progression of the original event should be reported as a follow-up to that event regardless of when it occurs. The follow-up information should describe whether the event has resolved or continues, if and how it was treated, whether the blind was broken or not, and whether the patient continued or withdrew from study participation.  
If the SAE is not previously docum ented in the Investigator’s Brochure or Package Insert (new 
occurrence) and is thought to be related to the [COMPANY_001]  study treatment, an oncology [COMPANY_001] 
Drug Safety and Epi[INVESTIGATOR_623] (DS&E) department associate may urgently require further information fro m the investigator for Health Authority reporting. [COMPANY_001] may need to issue an 
Investigator Notification (IN), to inform all investigators involved in any study with the same drug that this SAE has been reported. Suspected Unexpected Serious Adverse Reactions (S[LOCATION_003]Rs) will be collected and reported to the competent authorities and relevant ethics committees in accordance with Directive 2001/20/EC or as per national regulatory requirements in participating countries.  
Pregnancies  
To ensure patient safety, each pregnancy occurring while the patient is on study treatment must be reported to [COMPANY_001] within 24 hours of learning of its occurrence. The pregnancy should be followed up to determine outcome, including spontaneous or voluntary termination, details of the birth, and the presence or absence of any birth defects, congenital abnormalities, or maternal and/or newborn complications. 
Pregnancy should be recorded on a Clinical Trial Pregnancy Form and reported by [CONTACT_36926][INVESTIGATOR_066] (DS&E). Pregnancy follow-up should be recorded on the same form and should include an assessment of the possible relationship to the study treatment any pregnancy outcome. Any SAE experienced during pregnancy must be reported on the SAE Report Form. 
Warnings and P recautions  
Additional safety information collected between IB updates will be communicated in the form of 
Investigator Notifications. This information will be included in the patient informed consent and should be discussed with the patient during the study as needed 
7.2.4 Evaluating Adverse Events 
An investigator who is a qualified physician will evaluate all adverse events according to the 
NCI Common Terminology for Adverse Events (CTCAE), version 4.0. Any adverse event which 
Products:  Pembrolizumab /Trametinib   UCDCC#259  
  v.Original  (05/09/2017)  
 
Page [ADDRESS_260569] each change of grade 
recorded on the adverse event case report forms/worksheets.  
All adverse events regardless of CTCAE grade must also be evaluated for seriousness.  
Table 20. Evaluating Adverse Events 
An investigator,  who is a qualified physician, will evaluate all adverse events as to:  
V4.0 CTCAE 
Grading  Grade 1  Mild; asymptomatic or mid symptoms; clinical or diagnostic observations only; 
intervention not indicated.  
 Grade 2  Moderate; minimal, local or noninvasive intervention indicated; limiting age -appropriate 
instrumental ADL.  
 Grade 3  Severe or medically significant but not immediately life -threatening; hospi[INVESTIGATOR_133604]; disabling; limiting self -care ADL.  
 Grade 4  Life threatening consequences; urgent intervention indicated.  
 Grade [ADDRESS_260570] that:  
 †Results in death ; or 
 †Is life threatening; or  places the subject, in the view of the investigator, at immediate risk of death from the 
event as it occurred (Note: This does not include an adverse event that, had it occurred in a more severe form, 
might have caused death.); or  
 †Results in a persiste nt or significant disability/incapacity  (substantial disruption of one’s ability to 
conduct normal life functions); or  
 †Results in or prolongs an existing inpatient hospi[INVESTIGATOR_059]  (hospi[INVESTIGATOR_216696], regardless of length of stay, even if the hospi[INVESTIGATOR_2138] a precautionary measure for continued observation. (Note: Hospi[INVESTIGATOR_19358] a pre-existing condition that has not 
worsened is not a serious adverse event.  A pre -existing condition is a clinical condition that is diagnosed 
prior to the use of a [COMPANY_006] product and is documented in the patient’s medical history.); or  
 †Is a congenital anomaly/birth defect  (in of fspring of subject taking the product regardless of time to 
diagnosis);or  
 Is a new cancer  (that is not a condition of the study)  (although not serious per ICH definition, is reportable to 
the Sponsor Investigator within 24 hours and to [COMPANY_006] within 2 wor king days to meet certain local 
requirements); or 
 Is an overdose  (whether accidental or intentional).  Any adverse event associated with an overdose is 
considered a serious adverse event for collection purposes. An overdose that is not associated with an  adverse 
event is considered a non -serious event of clinical interest and must be reported within [ADDRESS_260571] and may require medical or surgical intervention to prevent one of the outcomes listed previously (designated above by a †).  
Duration  Record the start and stop dates of the adverse event. If less than [ADDRESS_260572] to be discontinued?  
 
 
Products:  Pembrolizumab /Trametinib   UCDCC#259  
  v.Original  (05/09/2017)  
 
Page [ADDRESS_260573] cause the adverse event? The determination of the likelihood that [COMPANY_006]  product  caused 
the adverse event will be provided by [CONTACT_19427] a qualified physician. The investigator’s signed/dated initials on the source document or worksheet that supports the causality noted on the AE form, 
ensures that a medically qualified as sessment of causality was done. This initialed document must be 
retained for the required regulatory time frame. The criteria below are intended as reference guidelines to assist the investigator in assessing the likelihood of a relationship between the te st drug and the adverse event 
based upon the available information.  
The following components are to be used to assess the relationship between [COMPANY_006] product and the 
AE; the greater the correlation with the components and their respective elements (in number and/or 
intensity), the more likely [COMPANY_006] product caused the adverse event (AE):  
Exposure  Is there evidence that the subject was actually exposed to [COMPANY_006] product such as: reliable 
history, acceptable compliance assessment (pi[INVESTIGATOR_692], diary, etc.), expected pharmacologic 
effect, or measurement of drug/metabolite in bodily specimen?  
Time Course  Did the AE follow in a reasonable temporal sequence from administration of [COMPANY_006] 
product?  
Is the time of onset of the AE compatible with a drug -induced effect (applies to trials with 
investigational medicinal product)?  
Likely Cause  Is the AE not reasonably explained by [CONTACT_26369], other 
drug(s)/vaccine(s), or other host or environmental factors  
Dechallenge  Was [COMPANY_006] product d iscontinued or dose/exposure/frequency reduced?  
If yes, did the AE resolve or improve?  
If yes, this is a positive dechallenge. If no, this is a negative dechallenge.  
(Note: This criterion is not applicable if: (1) the AE resulted in death or permanent disability; (2) the AE resolved/improved despi[INVESTIGATOR_130980]; or (3) 
the trial is a single -dose drug trial); or (4) [COMPANY_006] product(s) is/are only used one time.)  
 Rechallenge  Was the subject re -exposed to [COMPANY_006] product in this study?  
If yes, did the AE recur or worsen?  
If yes, this is a positive rechallenge. If no, this is a negative rechallenge.  
(Note: This criterion is not applicable if: (1) the initial AE resulted in death or permanent disability, or (2) the trial is a single -dose drug  trial); or (3) [COMPANY_006] product(s) is/are used 
only one time).  
NOTE: IF A RECHALLENGE IS PLANNED FOR AN ADVERSE EVENT WHICH 
WAS SERIOUS AND WHICH MAY HAVE BEEN CAUSED BY [CONTACT_131889], 
OR IF REEXPOSURE TO MERCK PRODUCT  POSES ADDITIONAL POTENTIAL 
SIGNIFICANT RISK TO THE SUBJECT, THEN THE RECHALLENGE MUST BE 
APPROVED IN ADVANCE BY [CONTACT_216764].  
 Consistency 
with Trial Treatment 
Profile  Is the clinical/pathological presentation of the AE consistent  with previous knowledge 
regarding [COMPANY_006] product or drug class pharmacology or toxicology?  
The assessment of relationship will be reported on the case report forms /worksheets by [CONTACT_19427] a qualified 
physician according to his/her best clinical judgment, including consideration of the above elements.  
Record one of the following  Use the following scale of criteria as guidance (not all criteria must be present to be 
indicative of [COMPANY_006] product relationship).  
Yes, there is a reasonable 
possibility of [COMPANY_006] product relationship.  There is evidence of exposure to [COMPANY_006] product.  The temporal sequence of the AE onset 
relative to the administration of [COMPANY_006] product is reasonable.  The AE is more likely explained by [CONTACT_131891].  
No, there is not a reasonable 
possibility of [COMPANY_006] product relationship  Subject did not receive the [COMPANY_006] product OR temporal sequence of the AE onset relative 
to administration of [COMPANY_006] product is not reasonable OR the AE is more likely explain ed 
by [CONTACT_78035].  (Also entered for a subject with overdose without an associated AE.)  
Products:  Pembrolizumab /Trametinib   UCDCC#259  
  v.Original  (05/09/2017)  
 
Page 70 of 87  
7.2.5 Sponsor Investigator Responsibility for Reporting Adverse Events  
All Adverse Events will be reported to regulatory authorities, IRB/IECs and investigators in 
accordance with all applicable global laws and regulations.  
 
8.[ADDRESS_260574] 3+3 design, starting at dose level 1. The 
decision to escalate to the next dose level will be determined by [CONTACT_216765]- limiting toxicity 
(DLT) observed during Cycle 2, with a cycle length defined as 3 weeks. Up to 3 patients will be 
initially enrolled in a dose cohort, starting at dose level 1. If 1 of 3 patients were to experience DLT, 3 additional patients will be enrolled at same dose level. If 0 of 3 patients or 1 of 6 patients enrolled at a dose level were to experience DLT, enrollment to next dose level will be opened. If 
>1 of 3 patients or >1 of 6 patients enrolled at a dose level were to experience DLT, the maximum tolerated dose (MTD) will have been exceeded. Adverse events will be collected and 
described for the expansion cohorts. Enrollment to dose level [ADDRESS_260575] dose level at which 0 of 3 patients or 1 of 6 patients experience DLT will be declared the MTD. A min imum of 6 patients and maximum of 18 patients will be enrolled for 
each cohort (Arm A: Lead in Trametinib and Arm B: Lead in Pembrolizumab) in this dose 
escalation portion of the study. 
Enrollment in to Cohorts A and B are pre-planned in regards to sequence and timing. Arm A 
(lead in trametinib) will open 1
st to dose escalation and will accrue 3 patients. Once 3 patients are 
accrued for Arm A, Arm B will open and accrue 3 patients. This is to ensure cohorts remain open for accrual given the 6 -week DLT period; these cohort s will alternate in opening in this fashion 
until the MTD is achieved for both Arm A and Arm B . Once the MTD is achieved for both Arms 
A and B, Arm A will open to dose expansion at the MTD and complete accrual, followed by [CONTACT_40845] B. If one Arm is delayed in opening additional dose levels due to toxicity, the alternate 
cohort may open at additional dose levels if approved by [CONTACT_216766].  
The recommended  dose expansion and recommended  phase II dose (RP2D) will be 
determined  by [CONTACT_216767].  
All patients who receive a dose of pembrolizumab and trametinib will be analyzed for safety and 
efficacy. Subjects who discontinue from study participation prior to receiving the combination of trametinib and pembrolizumab  will be replaced. Subjects in dose escalation who discontinue 
from study and are not evaluable for dose limiting toxicities will be replaced. Patients removed from study for unacceptable treatment related adverse event(s) will be followed until resolution or stabilization of all treatment related AEs to grade 2 or lower. However, they will not be replaced.  
Products:  Pembrolizumab /Trametinib   UCDCC#259  
  v.Original  (05/09/2017)  
 
Page 71 of 87 A group of 12 patients will be enrolled in each of the 2 expansion cohorts at the MTD . Patients 
will enroll into the next subsequent cohort upon completion of the previous cohort (Arm A then 
Arm B). A sequencing scheme will be considered as promising if at least [ADDRESS_260576] 1.1. The decision rule is associated with 80% exact power with an exact alpha of 0.[ADDRESS_260577] 50% compared to current expectation of 2 5% ORR with 
single agent pembrolizumab. A median PFS of [ADDRESS_260578] a difference compared to historical PFS of about 4 months with single agent pembrolizumab with an alpha of 0.1 based on accrual time of 24 months and follow up of 12 months. A sequencing scheme will be recommended for further development based on a combination of promising efficacy (response rate, PFS) and favorable changes in the tumor immune microenvironment at rebiopsy, provided the safety and tolerability profiles are acceptable.   
Assays will be performed at the SU2C Lung Cancer Dream Team Im mune Monitoring Core, 
Yale University, The Broad Institute, UCSF and at UC Davis Comprehensive Cancer Center as 
part of the SU2C Dream Team Lung Cancer Collaboration. Next generation sequencing by [CONTACT_216768]/RNA sequencing  to confirm KRAS amino acid 
substitution and examine mutational load and other co- mutations of interest  and well as changes 
in RNA expression of relevant gene in the tumor immune microenvironment. A subset analysis will explore clinical outcome by [CONTACT_216769] (G12C vs. non-G12C). The 
immune correlative studies performed in baseline and repeat biopsy specimens include: (in order of priority) 1) IHC and IF to determine PD-L1 expression, MEK target inhibition 2) additional 
immunophenotypi[INVESTIGATOR_007], and functional assessment of tumor infiltrating immune cells  3) Luminex 
evaluation of local tumor cytokine / chemokine signatures. In blood, FACS for quantification, immunophenotypi[INVESTIGATOR_007], and functional assessment of PBMCs will also be performed. 
Adverse events will be summarized descriptively by [CONTACT_216770], with number and 
relative frequency calculated for all non -zero occurrences. With [ADDRESS_260579] an 81% chance of seeing one or more cases of any adverse event that occurs in 10% or more patients.  
All molecular and immune correlates will be assessed in exploratory analyses. Due to the limited 
sample size and exploratory framework, any such analysis will be stated carefully as hypothes is-
generating with the reported p -values not adjusted for multiple comparisons. Standard 
descriptive and graphical methods will be used to summarize the baseline levels and post-treatment changes for comparison of the three MEKi and pembrolizumab sequencing schemes, which will allow us to examine whether observed patterns are consistent with hypothesized mechanisms. The quantitative immune studies will be compared using a t- test to further inform 
the decision. Multiplicity of testing will not be considered since this considered an exploratory 
analysis. Association with response rate will be summarized descriptively by [CONTACT_216771], SD, and other characteristics of molecular and immune measures, stratified by [CONTACT_27945]. Associations of molecular and immune measures with  PFS will be summarized 
descriptively by [CONTACT_216772] -Meier curves and, if numbers permit, by [CONTACT_216773]. If the MEKi and pembrolizumab combination were not found to have sufficient activity, the molecular and immune patterns may 
Products:  Pembrolizumab /Trametinib   UCDCC#259  
  v.Original  (05/09/2017)  
 
Page 72 of 87 help explain the lack of activity. If sufficient activity were observed, then the correlates will be 
compared between patients who experience an objective response and those who did not. Results of these correlative studies including biopsies at pre- treatment and week 1 on treatment will be 
analyzed in conjunction with the Battle- Immunotherapy trial (with its later biopsy correlative 
timepoints) to inform the optimal dosing and sequencing of pembrolizumab with trametinib.  
Decisions for whether to pursue one of these strategies in a larger trial will incorporate ORR, 
toxicity and immune correlative endpoints in collaboration with the company sponsors and SU2C Dream Team. The primary conside rations will be ORR and toxicity, with immune and 
genomic correlative studies used as supplementary criteria.  
If only one arm meets safety criteria and preliminary efficacy criteria (ORR ≥ 50% or a median 
PFS ≥ 8 months), then that treatment will be consi dered for future study. Immune and genomic 
correlative studies will be examined for the potential to inform future study design for that arm.  
If both arms A and B meet the safety criteria and preliminary efficacy criteria and give 
comparable response rates  and toxicities, we will carry out two additional sets of analyses to 
inform the decision process of which treatment to pursue for further study. First, we will use regression models to assess whether one arm might have superior performance after accounting for key patient differences (PD -L1 status, KRAS amino acid substitution (G12C vs. non-G12C), 
smoking status). We will assess whether one arm has superior ORR, using logistic regression analysis to control for clinical covariates, and whether one arm has superior PFS, usi ng 
proportional hazards models to control for clinical covariates. Second we Second, we will examine biomarkers that might shed light on the impact of the treatments. We will compare 
exploratory immune correlates (enhanced tumor immune microenvironment). The final decision will be based on best clinical judgment of all investigators.  
We expect that the distribution of PD-L1 expression in Arm A and Arm B to be comparable. Based on the current indication for first line pembrolizumab in PD-L1 high (>50%) NSCLC, the majority of patients accrued into this second line trial will likely contain tumors  with lower PD -
L1 expression. At completion of Arm A we will review baseline characteristics and current clinical practice at that time to assess whether it is anticip ated there would be a shift in biomarker 
distribution in Arm B.  
 
  
Products:  Pembrolizumab /Trametinib   UCDCC#259  
  v.Original  (05/09/2017)  
 
Page [ADDRESS_260580] Name & Potency  Dosage Form  
Pembrolizumab  50 mg  Lyophilized Powder for Injection  
Pembrolizumab  100 mg/ 4mL  Solution for Injection  
 
9.2 Trametinib  
Trametinib tablets are provided as immediate release tablets for oral administration containing 
trametinib dimethyl sulfoxide ([COMPANY_004]1120212B) equivalent to 0.125 mg, 0.5 mg or 2 mg of trametinib. All formulation excipi[INVESTIGATOR_216697]. Refer to the trametinib Investigator's Brochure for a list of excipi[INVESTIGATOR_840].  
The trametinib tablets are packaged in high -density polyethylene bottles with labels bearing the 
appropriate label text as required by [CONTACT_9071]. All study drug will be dispensed in child-resistant packaging.  
Refer to the Pharmacy Manual/site investigational product manual for additional guidance on 
study drug storage, preparation and handling. 
Study drug labels will contain information to  meet the applicable regulatory requirements.  
Classification  
Cytotoxic drug: molecular targeted cytotoxic drug  
Mechanism of Action  
Trametinib is a reversible inhibitor of mitogen -activated extracellular signal regulated kinase 1 
256 (MEK1) and MEK2 activation and of MEK1 and MEK2 kinase activity. MEK proteins are 
257 upstream regulators of the extracellular signal -related kinase (ERK) pathway, which 
promotes [ADDRESS_260581] which includes MEK1 and MEK2. Trametinib inhibits BRAF V600 mutation -positive 260 melanoma cell growth in vitro and in vivo. 
Products:  Pembrolizumab /Trametinib   UCDCC#259  
  v.Original  (05/09/2017)  
 
Page 74 of 87 Metabolism  
Trametinib is metabolized predominantly via deacetylation alone or with mono282 oxygenation 
or in combination with glucuronidation biotransformation pathways in vitro. 283 Deacetylation is likely mediated by [CONTACT_216774], such as carboxyl -esterases or amidases. 284 Following 
a single dose of [14C]- trametinib, approximately 50% of circulating radioactivity is 28 5 
represented as the parent compound. However, based on metabolite profiling after repeat dosing 286 of trametinib, > 75% of drug- related material in plasma is the par ent compound. 
 
Contraindications 
None.  
Availability  
Trametinib will be supplied by [CONTACT_216775]. 
Storage and H andling  
Trametinib tablets should be stored refrigerated at 2° to 8°C (36° to 46°F). Do not freeze. 
Dispense in original bottle. Do not remove desiccant. Protect from moisture and light. Do not place medication in pi[INVESTIGATOR_16582].  
Side Effects  
Complete and updated adverse event information is available in the Investigational Drug Brochure and/or product package insert. 
9.3 Packaging and Labeling Information 
Clinical supplies will be affixed with a clinical label in accordance with regulatory requirements.  
9.4 Clinical Supplies Disclosure  
This trial is open -label; therefore, the subject, the trial site personnel, the Sponsor Investigator 
and/or designee are not blinded to treatment. Drug identity (name, strength) is included in the 
label text; rand om code/disclosure envelopes or lists are not provided. 
9.[ADDRESS_260582] be recorded by [CONTACT_80098]. 
Clinical supplies may not be used for any purpose other than that stated in the protocol. 
Products:  Pembrolizumab /Trametinib   UCDCC#259  
  v.Original  (05/09/2017)  
 
Page 75 of 87 9.6 Returns and Reconciliation  
The investigator is responsible for keepi[INVESTIGATOR_216698] /[COMPANY_001]  or designee, the amount dispensed to and returned by [CONTACT_26383].  
Upon completion  or termination  of the study,  all unused and/or partially used investigational 
product will be destroyed at the site per institutional policy.  It is the Investigator ’s respons ibility  
to arrange for disposal of all empty containers, provided that procedures for proper disposal 
have been established according to applicable federal, state, local and institutional guidelines and 
procedures, and provided that appropriate records of disposal are kept.  
10.[ADDRESS_260583] confiden ce according to legal requirements.  The 
investigator will grant monitor(s) and auditor(s) from [COMPANY_006] or its designees and regulatory authority(ies) access to the patient’s original medical records for verification of data gathered on the data capture reco rds and to audit the data collection process.  The patient’s confidentiality 
will be maintained and will not be made publicly available to the extent permitted by [CONTACT_4913]. 
10.2 Good Clinical Practice  
The study will be conducted in accordance with the International Conference on Harmonisation 
(ICH) for Good Clinical Practice (GCP) and the appropriate regulatory requirement(s).  The investigator will be thoroughly familiar with the appropriate use of the drug as described in the protocol and Investigator’s Brochure.  Essential clinical documents will be maintained to demonstrate the validity of the study and the integrity of the data collected.  Master files should be established at the beginning of the study, maintained for the duration of the study and retained according to the appropriate regulations. 
10.3 Patient Information and Informed Consent  
After the study has been fully explained, written informed consent will be obtained from either 
the patient or his guardian or legal representativ e prior to study participation.  The method of 
obtaining and documenting the informed consent and the contents of the consent will comply with ICH -GCP and all applicable regulatory requirement(s).  In accordance with UCD OCR 
policy an original signed and dated participant Informed Consent document will reside in a secured location within the UCD OCR.  Copi[INVESTIGATOR_216699]:  Pembrolizumab /Trametinib   UCDCC#259  
  v.Original  (05/09/2017)  
 
Page 76 of 87 Management for inclusion in the participant’s UCD Health System Medical Record or per 
participating site’s policies.  
10.4 Records and Retention  
The investigator will maintain all study records according to ICH -GCP and applicable regulatory 
requirement(s).   
10.[ADDRESS_260584] to the UC Davis Cancer Center’s (UCDCC) Data and Safety Monitoring Plan. The UCDCC is committed to pursuing high- quality patient -oriented clinical research and has es tablished mechanisms to 
ensure both scientific rigor and patient safety in the conduct of clinical research studies. The UCDCC relies on a multi- tiered committee system that reviews and monitors all cancer clinical 
trials and ensures the safety of its part icipants, in compliance with institutional and federal 
requirements on adverse event (AE) reporting, verification of data accuracy, and adherence to protocol eligibility requirements, treatment guidelines, and related matters. The Scientific Review Committee (SRC) assumes overall oversight of cancer studies, with assistance and input from two independent, but interacting, committees: the Quality Assurance Committee and the Data Safety Monitoring Committee. A multi- level review system strengthens the ability  of the 
UCDCC to fulfill its mission in conducting high quality clinical cancer research.  
As per University of [LOCATION_004] Davis Cancer Center (UCDCC) Office of Clinical Research (OCR) SOP AM 506: Protocol Specific Meetings, the principal investigator (PI) and clinical research coordinator (CRC) meet at least monthly for ongoing study information, to discuss patient data and adverse events and to determine if dose escalation is warranted, when applicable.  Because this is a phase I study, a meeting and/or conference call will take place when the last subject on each cohort completes DLT (dose- limiting toxicity) assessment.  The 
meeting and/or call will update the attendees of the current status of the study and will include investigators from all participatin g centers, and, if necessary, representatives from the drug 
provider or financial supporter.  All serious adverse events experienced by [CONTACT_216776].  If serious adverse events occur between these meetings and/or calls, all investigators will be informed by [CONTACT_6968].  
According to the UCDCC Data and Safety Monitoring Plan (DSMP), any new serious adverse events related to the drugs being used on this trial are reviewed monthly by [CONTACT_216777] (DSMC) and any applicable changes to the study are 
recommended to the PI, if necessary.  
The UCDCC Scientific Review Committee (SRC) determines if a UCDCC Data and Safety Monitoring Board (DSMB) is required.  If required, the DSMC will appoint a DSMB. The DSMB is responsible for reviewing study accrual logs, adverse event information and dose escalation meeting minutes (where applicable) to ensure subject safety and compliance with protocol defined guidelines. 
Products:  Pembrolizumab /Trametinib   UCDCC#259  
  v.Original  (05/09/2017)  
 
Page 77 of 87 10.6 Compliance with Law  and Reg ulations 
This study will be conducted in accordance with current US Food and Drug Administration 
(FDA) Good Clinical Practices (GCPs), International Conference on Harmonization (ICH) guidelines and local ethical and legal requirements. Specifically, the st udy will be conducted 
under a protocol reviewed by [CONTACT_2717]; the study will be conducted by [CONTACT_63043]; the benefits of the study are in proportion to the risks; the rights and welfare of the subjects will be respected; th e physicians conducting the study do not find the hazards to 
outweigh the potential benefits; and each subject will give his or her written, informed consent before any protocol-driven tests or evaluations are performed. All patients will have signed an informed consent for participation in research activities in accord with all institutional, NCI and Federal regulations, and will have been given a copy of the Experimental Subject's Bill of Rights.  
10.[ADDRESS_260585] (FDAMA) and the Food and Drug Administration Amendments Act (FDAAA), the Sponsor Investigator  of the trial 
is solely responsible for determining whether the trial and its results are subject to the requirements for submission to the Clinical Trials Data Bank, http://www.clinicaltrials.gov.  Information posted will allow subjects to identify potentially appropriate trials for their disease conditions and pursue participation by [CONTACT_3379] a central contact [CONTACT_57426].     
10.[ADDRESS_260586] patients and source documents may be conducted by [CONTACT_216778].  
Quality control will be maintained by [CONTACT_216779]. 
  
Products:  Pembrolizumab /Trametinib   UCDCC#259  
  v.Original  (05/09/2017)  
 
Page [ADDRESS_260587](s) in 
stock.  
B. Registrations must be made through the Office of Clinical R esearch (OCR) of the University 
of [LOCATION_004], Davis Comprehensive Cancer Center between the hours of 9am and 3pm (Pacific Time), Monday through Friday (except holidays).  Documentation of current IRB approval of this protocol must be on file prior to regi stration of patients.  
C. Slot reservation. Prior to consenting, email the UCD team the following  information: patient 
initials and anticipated start date. Confirmation of slot reservation will be emailed back to 
the site  within [ADDRESS_260588] and reports from all pre-study laboratory tests, scans and x- rays (where 
applicable)  must be faxed to UC Davis Study Coordinator in order to register the patient. 
These documents are to be reda cted and the “patient initials” or “a participating site subject 
identifier” will be written on the documents until the Study Subject ID is issued. The UC Davis Study Coordinator will review these documents and fax and/or email a registration confirmation (which includes a subject ID number). 
F. Reminder: Confirm eligibility of ancillary studies and willingness to participate at the same time as eligibility for the treatment study.  
G. If the patient is to be registered the same day as the proposed treatment  start date, the UC 
Davis Study Coordinator must be notified by [CONTACT_6791] [ADDRESS_260589] the coordinating site PI [INVESTIGATOR_216700].   
NOTE: Administration of study medication may not be initiated until the registration 
confirmation has been received.    
Products:  Pembrolizumab /Trametinib   UCDCC#259  
  v.Original  (05/09/2017)  
 
Page 79 of 87 11.2     Data Management 
All data will be collected us ing UC Davis data collection forms. Any and all source 
documentation should be maintained. 
 SUBMIT WITHIN 24 HOURS OF REGISTRATION:  
Patient Registration Form  
 SUBMIT WITHIN 14 DAYS OF REGISTRATION:  
In‐House Pre ‐Study Evaluation Form (IH ‐102)  
 SUBMIT WITHIN 7 DAYS OF SCREENING FAILURE :  
Patient Screen Failure Form  
 SUBMIT WITH 14 DAYS OF CYCLE COMPLETION:  
Advers e Event -Drug Relationship Form  
 SUBMIT WITHIN 14 DAYS OF END OF EACH TREATMENT CYCLE :  
In‐House Treatment Cycle Form (IH ‐201)  
 SUBMIT WITHIN 14 DAYS OF OFF TREATMENT :  
Off Treatment/In Follow -up/Off Study/Expi[INVESTIGATOR_91818] (IH ‐301)  
 SUBMIT WITHIN 14 DAYS OF KNOWLEDGE OF DEATH IF PATIENT IS STILL 
ON STUDY OR 30 –DAYS IF OFF STUDY :  
Off Treatment/In Follow -up/Off Study/Expi[INVESTIGATOR_91818] (IH ‐301)  
 SUBM IT WITHIN 2 DAYS OF KNOWLEDGE OF PROTOCOL DEVIATION:  
Clinical Trials Support Unit: Notice of Protocol Deviation  
 SUBMIT WITHIN 14 DAYS OF EACH REQUIRED FOLLOW ‐UP ENCOUNTER : 
Follow ‐Up Form (IH ‐302)  
 ALL SERIOUS ADVERSE EVENTS MUST BE REPORTED AS OUTLINED IN THE 
PROTOCOL  
 
  
Products:  Pembrolizumab /Trametinib   UCDCC#259  
  v.Original  (05/09/2017)  
 
Page 80 of 87 11.3 ECOG Performance Status  
Grade  Description  
0 Normal activity. Fully active, able to carry on all pre -disease 
performance without restriction.  
1 Symptoms, but ambulatory. Restricted in physically strenuous 
activity, but ambulatory and able to carry out work of a light or 
sedentary nature (e.g., light housework, office work). 
2 In bed <50% of the time. Ambulatory and capable of all self -care, 
but unable to carry out any work activities. Up and about more than 50% of waking hours. 
3 In bed >50% of the time. Capable of only limited self -care, confined 
to bed or chair more than 50% of waking hours. 
4 100% bedridden. Completely disabled. Cannot carry on any self -
care. Totally confined to bed or chair. 
5 Dead.  
* As published in Am. J. Clin. Oncol.:  Oken, M.M., Creech, R.H., Tormey, D.C., Horton, J., Davis, T.E., 
McFadden, E.T., Carbone, P.P.: Toxicity And Response Criteria Of The Eastern Cooperative Oncology Group. 
Am J Clin Oncol 5:649-655, 1982. The Eastern Cooperative Oncology Group, Robert Comis M.D., Group Chair.  
 
  
  
Products:  Pembrolizumab /Trametinib   UCDCC#259  
  v.Original  (05/09/2017)  
 
Page 81 of 87 11.4 FRIDERICIA’S CRITERIA FOR QTC CALCULATION  
Fridericia’s formula QTcF = (QT/RR^0.33). RR is the time from the interval of 1 QRS complex 
to the next measured in seconds and  is commonly calculated as (60/HR) (Hosmane et al, Journal 
of Applied Research 2006). 
 
  
Products:  Pembrolizumab /Trametinib   UCDCC#259  
  v.Original  (05/09/2017)  
 
Page 82 of 87 11.5 [LOCATION_001] Heart Association Classification of Heart Failure 
 
Class  Patient Symptoms  
Class I (Mild)  No limitation of physical activity.  
Ordinary physical activity does  not cause undue fatigue, 
palpi[INVESTIGATOR_332], or dyspnea (shortness of breath) 
Class II (Mild)  Slight limitation of physical activity.  
Comfortable at rest, but ordinary physical activity results in 
fatigue, palpi[INVESTIGATOR_332], or dyspnea. 
Class III  (Moderate)  Marked limitation of physical activity.  
Comfortable at rest, but less than ordinary activity causes fatigue, palpi[INVESTIGATOR_332], or dyspnea. 
Class IV (Severe)  Unable to carry out any physical activity without discomfort.  
Symptoms of cardiac insufficiency at rest.  
If any physical activity is undertaken, discomfort is increased. 
 
    
  
Products:  Pembrolizumab /Trametinib   UCDCC#259  
  v.Original  (05/09/2017)  
 
Page 83 of 87 11.6 Common Terminology Criteria for Adverse Events V4.0 (CTCAE) 
The descriptions and grading scales found in the revised NCI Common Terminology Criteria for 
Adverse Events (CTCAE) version 4.0 will be utilized for adverse event reporting. (http://ctep.cancer.gov/reporting/ctc.html)  
  
Products:  Pembrolizumab /Trametinib   UCDCC#259  
  v.Original  (05/09/2017)  
 
Page 84 of 87 11.7 Response Evaluation Criteria in Solid Tumors (RECIST) 1.[ADDRESS_260590] version 1.1* will be used in this study for assessment of tumor response. While either 
CT or MRI may be utilized, as per RECIST 1.1, CT is the preferred imaging technique in this study.  
* As published in the European Journal of Cancer: 
E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, R. Ford, J. Dancey, S. 
Arbuck, S. Gwyther, M. Mooney, L. Rubinstein, L. Shankar, L. Dodd, R. Kaplan, D. Lacombe, J. Verweij. New response evaluation criteria in solid tumors: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan;45(2):228-47. 
In addition, volumetric analysis will be explored by [CONTACT_133630].  
  
  
Products:  Pembrolizumab /Trametinib   UCDCC#259  
  v.Original  (05/09/2017)  
 
Page 85 of 87 11.8 Drug Diary  
D1-10 DOSING  
Protocol Number:  UCDCC#259 
Patient Name: _________________________________ Medical Record  #: _____________ 
Cycle #:  ____________ Start Date:  ________________ Dose:  __________________ 
Instructions:  Please record the time that you take your study medications. Return this diary, the 
medication  bottles (even if empty or unopened), and any unused tablets at your next clinic visit 
and make sure you are given another diary. 
Store your study medication in the original bottle in the refrigerator (2°C to 8°C). Temperature 
excursions should be limited to the time it takes for you to transport your study medication from the clinic/hospi[INVESTIGATOR_216701].  
Trametinib c omes in a tablet form and should be taken by [CONTACT_216780] [ADDRESS_260591] 1 hour before  or 2 hours after a meal.  
D1-10 Dosing 
Day Date  
(mm/dd/yy)  Dose  
(mg)  Time Taken  Notes  
1     
2     
3     
4     
5     
6     
7     
8     
9     
10     
 
 
Signature [CONTACT_2385]:   ___________________ _____________ Date:  __________  
Products:  Pembrolizumab /Trametinib   UCDCC#259  
  v.Original  (05/09/2017)  
 
Page 86 of 87 D1-7 DOSING  
Protocol Number:  UCDCC#259 
Patient Name: _________________________________ Medical Record  #: _____________ 
Cycle #:  ____________ Start Date:  ________________ Dose:  __________________ 
Insructions:  Please record the time that you take your study medications. Return this diary, the 
medication  bottles (even if empty or unopened), and any unused tablets at your next clinic visit 
and make sure you are given another diary. 
Store your study medication in the original bottle in the refrigerator (2°C to 8°C). Temperature 
excursions should be limited to the time it takes for you to transport your study medication from the clinic/hospi[INVESTIGATOR_216701].  
Trametinib comes in a tablet form and should be taken by [CONTACT_216780] [ADDRESS_260592] 1 hour before  or 2 hours after a meal.  
D1-7 Dosing 
Day Date  
(mm/dd/yy)  Dose  
(mg)  Time Taken  Notes  
1     
2     
3     
4     
5     
6     
7     
 
 Signature [CONTACT_2385]:   ________________________________ Date:  __________ 
  
Products:  Pembrolizumab /Trametinib   UCDCC#259  
  v.Original  (05/09/2017)  
 
Page [ADDRESS_260593], SnapShot: Ras Signaling. Cell, 2008. 133(7): p. 1292-1292 
e1. 
2. Janne, P.A., et al., Selumetinib plus docetaxel for KRAS-mutant advanced non- small -cell 
lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. The lancet 
oncology, 2013. 14 (1): p. 38-47. 
3. David  R. Gandara, S.H., George R. Blumenschein, Fabrice Barlesi, Jean- Pi[INVESTIGATOR_216702], 
Jeannick Madelaine, Jeffrey R. Infante, Karen L. Reckamp, Primo Lara, Christine Audebert, By[CONTACT_216781], Keunchil Park, Fadi S. Braiteh, Robert M. Jotte, Yuehui Wu, Daniel J. Schramek, Alexandra M. Pi[INVESTIGATOR_216703], Olivia S. Gardner, Vijay Gopal Reddy Peddareddigari, Natasha B. Leighl, Oral MEK1/MEK2 inhibitor trametinib ([COMPANY_004]1120212) in combination with docetaxel in KRAS-mutant and wild- type (WT) 
advanced non-small cell lung cancer (NSCLC): A phase I/Ib trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013. 31: p. suppl; abstr 8028. 
4. Jiang, X., et al., The activation of MAPK in melanoma cells resistant to BRAF inhibition 
promotes PD-L1 expression that is reversible by [CONTACT_216782]3K inhibition. Clinical cancer research : an official journal of the American Association for Cancer Research, 2013. 19(3): p. 598-609. 
5. Frederick, D.T., et al., BRAF inhibition is associated with enhanced melanoma antigen 
expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2013. 19(5): p. 1225-31. 
6. Yamamoto, R., et al., B7 -H1 expression is regulated by [CONTACT_216711]/ERK signaling pathway in 
anaplastic large cell lymphoma and Hodgkin lymphoma. Cancer science, 2009. 100(11): p. 2093-100. 
7. Carter, C.A., et al., Selumetinib with and without erlotinib in KRAS mutant and KRAS 
wild-type advanced non-small cell lung cancer. Ann Oncol, 2016. 
8. Liu, L., et al., The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4. Clin Cancer Res, 2015. 21(7): p. 1639-51. 
9. Balagula, Y., et al., Dermatologic side effects associated with the MEK 1/2 inhibitor 
selumetinib (AZD6244, ARRY-142886). Invest New Drugs, 2011. 29(5): p. 1114-21. 
10. Lacouture, M.E., et al., Clinical practice guidelines for the prevention and treatment of 
EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer, 2011. 19(8): p. 1079-95. 
11. Schalper, K.A., et al., Objective measurement and clinical significance of TILs in non-
small cell lung cancer. J Natl C ancer Inst, 2015. 107(3).  
12. Garon, E.B., et al., Pembrolizumab for the treatment of non- small -cell lung cancer.  N 
Engl J Med, 2015. 372(21): p. 2018-28. 
 